Mass deworming for improving health and cognition of children in endemic helminth areas: A systematic review and individual participant data network meta-analysis

Welch, Vivian A.; Ghogomu, Elizabeth; Hossain, Alomgir; Riddle, Alison; Gaffey, Michelle; Arora, Paul; Dewidar, Omar; Salaam, Rehana; Cousens, Simon; Black, Robert; Hollingsworth, T. Déirdre; Horton, Sue; Tugwell, Peter; Bundy, Donald; Castro, Mary Christine; Elliott, Alison; Friis, Henrik; Le, Huong T; Liu, Chengfang; Rousham, Emily K; Rohner, Fabian; King, Charles; Sartono, Erliyani; Supali, Taniawati; Steinmann, Peter; Webb, Emily; Wieringa, Franck; Winnichagoon, Pattanee; Yazdanbakhsh, Maria; Bhutta, Zulfiqar A; Wells, George

Published in:
Campbell Systematic Reviews

DOI:
10.1002/cl2.1058

Publication date:
2019

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY

Citation for published version (APA):
Welch, V. A., Ghogomu, E., Hossain, A., Riddle, A., Gaffey, M., Arora, P., Dewidar, O., Salaam, R., Cousens, S., Black, R., Hollingsworth, T. D., Horton, S., Tugwell, P., Bundy, D., Castro, M. C., Elliott, A., Friis, H., Le, H. T., Liu, C., ... Wells, G. (2019). Mass deworming for improving health and cognition of children in endemic helminth areas: A systematic review and individual participant data network meta-analysis. Campbell Systematic Reviews, 15(4), [e1058]. https://doi.org/10.1002/cl2.1058
SYSTEMATIC REVIEW

Mass deworming for improving health and cognition of children in endemic helminth areas: A systematic review and individual participant data network meta-analysis

Vivian A. Welch1,2 | Elizabeth Ghogomu3 | Alomgir Hossain4 | Alison Riddle2 | Michelle Gaffey5 | Paul Arora6 | Omar Dewidar3 | Rehana Salam 7 | Simon Cousens8 | Robert Black9 | T. Déirdre Hollingsworth10 | Sue Horton11 | Peter Tugwell2,12 | Donald Bundy13 | Mary Christine Castro14 | Alison Elliott15 | Henrik Friis16 | Huong T. Le17 | Chengfang Liu18 | Emily K. Rousham19 | Fabian Rohner20 | Charles King21 | Erliyani Sartono22 | Taniawati Supali23 | Peter Steinmann24 | Emily Webb25 | Franck Wieringa26 | Pattanee Winnichagoon27 | Maria Yazdanbakhsh22 | Zulfiqar A. Bhutta28* | George Wells4*

1Centre for Global Health, Bruyère Research Institute, Ottawa, Ontario, Canada
2School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ottawa, Ontario, Canada
3Bruyère Research Institute, University of Ottawa, Ottawa, Ontario, Canada
4Cardiovascular Research Methods, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
5Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
6Public Health Agency of Canada in the National Public Health Laboratory and Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
7South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia
8London School of Hygiene and Tropical Medicine (LSHTM), London, UK
9Department of International Health, Johns Hopkins School of Hygiene and Public Health, Baltimore, Maryland
10Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK
11School of Public Health and Health Systems, University of Waterloo, Waterloo, Ontario, Canada
12Center for Global Health, WHO Collaborating Centre for Knowledge Translation and Health Technology Assessment in Health Equity, Bruyère Research Institute, Ottawa, Ontario, Canada
13Bill & Melinda Gates Foundation, London, UK
14Nutrition Center of the Philippines, Manila, Philippines
15Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
16Department of Human Nutrition, University of Copenhagen, Frederiksberg, Denmark
17Institute for Preventive Medicine and Public Health, Hanoi Medical University, Hanoi, Vietnam
18School of Advanced Agricultural Sciences (SAAS), China Center for Agricultural Policy (CCAP), Peking University, Beijing, China
19School of Sport, Exercise and Health Sciences, Loughborough University, Leicestershire, UK
20GroundWork, Fläsch, Switzerland
21Department of Pediatrics, University of California, La Jolla, California
22Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands
23Department Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

*Zulfi Bhutta and George Wells are joint senior authors.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2019 The Authors. Campbell Systematic Reviews published by John Wiley & Sons Ltd on behalf of The Campbell Collaboration
Abstract

Background: Soil transmitted (or intestinal) helminths and schistosomes affect millions of children worldwide.

Objectives: To use individual participant data network meta-analysis (NMA) to explore the effects of different types and frequency of deworming drugs on anaemia, cognition and growth across potential effect modifiers.

Search Methods: We developed a search strategy with an information scientist to search MEDLINE, CINAHL, LILACS, Embase, the Cochrane Library, Econlit, Internet Documents in Economics Access Service (IDEAS), Public Affairs Information Service (PAIS), Social Services Abstracts, Global Health CABI and CAB Abstracts up to March 27, 2018. We also searched grey literature, websites, contacted authors and screened references of relevant systematic reviews.

Selection Criteria: We included randomised and quasirandomised deworming trials in children for deworming compared to placebo or other interventions with data on baseline infection.

Data Collection and Analysis: We conducted NMA with individual participant data (IPD), using a frequentist approach for random-effects NMA. The covariates were: age, sex, weight, height, haemoglobin and infection intensity. The effect estimate chosen was the mean difference for the continuous outcome of interest.

Results: We received data from 19 randomized controlled trials with 31,945 participants. Overall risk of bias was low. There were no statistically significant subgroup effects across any of the potential effect modifiers. However, analyses showed that there may be greater effects on weight for moderate to heavily infected children (very low certainty evidence).

Authors’ Conclusions: This analysis reinforces the case against mass deworming at a population-level, finding little effect on nutritional status or cognition. However, children with heavier intensity infections may benefit more. We urge the global community to adopt calls to make data available in open repositories to facilitate IPD analyses such as this, which aim to assess effects for the most vulnerable individuals.

1 | PLAIN LANGUAGE SUMMARY

Mass deworming programmes have little effect on nutritional status and cognitive development on a population level.

1.1 | The Campbell review in brief

The effectiveness and cost-effectiveness of mass deworming of children to improve child health and other outcomes is debated. This independent analysis reinforces the case against mass deworming at a population-level, finding little effect on nutritional status or cognition. However, children with heavier intensity infections may benefit more.

1.2 | What is this review about?

Soil-transmitted helminthiasis (STH) and schistosomiasis affects over 800 million people. There is ongoing debate about whether mass deworming of children improves child nutritional status and cognitive development in endemic areas.

1.2.1 | What studies are included?

Randomised trials of mass deworming for STH (alone or in combination with other drugs or child health interventions) for children aged 6 months to 16 years were eligible if they reported at least one of the following outcomes: growth, haemoglobin, serum ferritin, or cognitive processing or
development. Trials had to collect data on baseline STH infection intensity, since the main purpose of this review was to assess effect modification across intensity of infection.

Individual participant data (IPD) was obtained from 19 out of 41 eligible randomised trials. These 19 trials included 31,945 participants and had an overall low risk of bias.

A secondary analysis added new data to the meta-analysis of STH deworming versus placebo of a previous Campbell review by the same authors. This analysis included 29 randomised trials, with data from two studies which had not published weight gain data and updated effect estimates from three studies based on the data provided by authors.

These studies were conducted in 11 low and middle income countries. Most programmes conducted deworming every 4 months or more frequently. Seven out of 19 studies gave a single dose of deworming. Children were school-age, with a median of 11 years of age.

1.3 | Does deworming improve child health and other welfare outcomes?

Mass deworming for STHs compared to placebo probably has little to no effect on nutritional status or cognitive development (moderate certainty evidence). Children with moderate to heavy intensity infections of *Ascaris lumbricoides* or *Trichuris trichiura* may experience greater weight gain (very low certainty evidence). No other differences in effects were found across age, sex or baseline nutritional status.

Findings are consistent for studies at low risk of bias and for other methodological considerations such as completer analyses. There was no trend in effect according to publication year, baseline A. lumbricoides prevalence or T. trichiura prevalence in the full dataset of 29 studies. Higher baseline hookworm prevalence was weakly associated with greater effects of STH deworming.

1.4 | What are the implications of this review for policy makers and decision makers?

This analysis replicates the prior findings of small effects of mass deworming at the population level. In areas where there are children with moderate to heavy intensity infections, which are increasingly uncommon, mass deworming may be beneficial, but this analysis was limited by the small number of children with heavy intensity infections in this sample (<1,000). In areas with light intensity infections, mass deworming programmes probably have very small effects on weight for these children and additional policy options need to be explored to improve child health and nutrition in these areas.

1.5 | What are the research implications of this review?

This analysis was severely limited by not being able to obtain IPD for many older studies, which may have included children with heavier intensity infections. Greater adoption of calls for open, structured data from trials could maximise the benefit of research to understand effects in the most vulnerable and marginalised populations within these trials.

Summary of findings table 1: Deworming with any STH drug compared to placebo for children in STH endemic areas

| Outcomes                                   | No. of participants (studies) | Direct evidence | Network meta-analysis |
|--------------------------------------------|------------------------------|----------------|----------------------|
| Weight (change in kg)                      | 11,024 (9 studies)           | 0.05 (−0.02, 0.11) | ⊕⊕⊕⊝        |
| Height (change in cm)                      | 11,024 (9 studies)           | 0.04 (−0.04, 0.11) | ⊕⊕⊕⊝        |
| Hemoglobin (change in g/L)                 | 11,024 (9 studies)           | 0.23 (−0.52, 0.97) | ⊕⊕⊕⊝         |
| Cognition                                  | 6 studies (5,814 participants) | There was little to no effect on cognitive outcomes measured on various scales for short-term attention, school achievement, developmental scales |

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

Note: Findings based on the analysis of main effects of 19 studies providing individual participant data.

Abbreviations: CI, confidence interval; IPD, individual participant data; STH, soil transmitted helminth.

a Downgraded for study limitations—obtained only a selected sample of IPD from 19 out of 41 eligible studies.

b Downgraded for imprecision.
### Summary of findings table 2: Deworming with praziquantel alone or in combination with any STH deworming compared to placebo for children in STH endemic areas

| Outcomes               | No. of participants (studies) | Direct evidence | Network meta-analysis |
|------------------------|------------------------------|-----------------|-----------------------|
|                        |                              | MD (95% CI)     | Quality of the evidence (GRADE) | MD (95% CI) | Quality of the evidence (GRADE) |
| Weight (change in kg)  | 2,171 (5 studies)            | 0.04 (−0.12, 0.20) | @@@ moderate^a | 0.04 (−0.11, 0.19) | @@@ moderate^a |
| Height (change in cm)  | 2,171 (5 studies)            | −0.10 (−0.44, 0.25) | @@@ moderate^a | −0.06 (−0.31, 0.18) | @@@ moderate^a |
| Hemoglobin (change in g/L) | 2,171 (5 studies) | 2.02 (0.93, 3.11) | @@@ moderate^a | 1.85 (0.53, 3.18) | @@@ low^ab |

**GRADE Working Group grades of evidence**

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

**Note:** Findings based on the analysis of main effects of 19 studies providing individual participant data.

Abbreviations: CI, confidence interval; STH, soil transmitted helminth.

^aDowngraded for study limitations—obtained only a selected sample of IPD from 19 out of 41 eligible studies.

^bDowngraded for imprecision.

### Summary of findings table 3: Deworming with any STH drug with iron or micronutrients compared to placebo for children in STH endemic areas

| Outcomes               | No. of participants (studies) | Direct evidence | Network meta-analysis |
|------------------------|------------------------------|-----------------|-----------------------|
|                        |                              | MD (95% CI)     | Quality of the evidence (GRADE) | MD (95% CI) | Quality of the evidence (GRADE) |
| Weight (change in kg)  | 3,851 (5 studies)            | 0.00 (−0.07, 0.08) | @@@ moderate^a | −0.02 (−0.15,0.12) | @@@ moderate^a |
| Height (change in cm)  | 3,851 (5 studies)            | 0.02 (−0.07, 0.11) | @@@ moderate^a | −0.03 (−0.27,0.22) | @@@ moderate^a |
| Hemoglobin (change in g/L) | 3,851 (5 studies) | 2.18 (1.02, 3.35) | @@@ moderate^a | 1.98 (0.74,3.21) | @@@ low^ab |

**GRADE Working Group grades of evidence**

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

**Note:** Findings based on the analysis of main effects of 19 studies providing individual participant data.

Abbreviations: CI, confidence interval; STH, soil transmitted helminth.

^aDowngraded for study limitations—obtained only a selected sample of IPD from 19 out of 41 eligible studies.

^bDowngraded for imprecision.
BACKGROUND

2.1 The problem, condition or issue

Soil transmitted (or intestinal) helminths and schistosomiasis affect millions of children worldwide. There are four species of STH: A. lumbricoides (roundworm), Necator americanus and Ankylostoma duodenale (hookworms), and Trichuris trichiura (whipworm). The five species of schistosomiasis which affect humans include: Schistosoma mansoni, Schistosoma japonicum, Schistosoma mekongi, Schistosoma intercalatum (which causes intestinal schistosomiasis) and Schistosoma haematobium (which causes urinary schistosomiasis).

Mass deworming is applied widely to reduce the consequences of helminth infection, and there have been numerous studies on the effects of deworming on growth, cognition and learning outcomes in children over the past several decades. Systematic reviews and meta-analyses based on aggregate results of the effect of mass deworming on health and education outcomes are conflicting with some showing benefit (Croke, Hicks, Hsu, Kremer, & Miguel, 2016; Hall, Hewitt, Tuffrey, & de, 2008) and others not (Taylor-Robinson, Maayan, Soares-Weiser, Donegan, & Garner, 2015; Welch et al., 2017). Debate has ensued about whether these conflicting results are due to the influence of variations in effect across individual-level characteristics such as whether children are infected or not and intensity of infection (Bundy, Kremer, Bleakley, Jukes, & Miguel, 2009; Hotez et al., 2007; Montresor et al., 2015) as well as setting characteristics such as the sanitation environment and rapidity of reinfection (Campbell et al., 2016).

2.2 The intervention

Mass deworming for STH infection and schistosomiasis is recommended one to four times per year in order to reduce worm burden in endemic areas in the updated World Health Organization guidelines, depending on prevalence of worm infection (WHO, 2017). These updated WHO guidelines cite the Campbell and Cochrane systematic reviews on deworming which both concluded there was little to no effect of deworming on child health outcomes which included growth, anaemia and cognitive outcomes (Taylor-Robinson et al., 2015; Welch et al., 2016). Mass deworming can be applied to school-aged children or whole communities. Selective treatment of infected individuals is rarely done due to the high cost of screening for infection.

The drugs used include albendazole, mebendazole, levamisole, ivermectin and piperazine for STH infection and praziquantel for schistosomiasis. These drugs are usually provided as pills, are inexpensive and can be administered by schoolteachers or parents. The drugs are considered to have few minor and transient side effects, such as gastrointestinal discomfort, headache, nausea, dizziness, oedema, myalgia and vomiting (WHO, 2017).

Mass deworming is sometimes accompanied by iron, micronutrient or food supplementation in order to correct nutritional deficiencies that may have been caused by worm infections (de Gier, Campos Ponce, van de Bor, Doak, & Polman, 2014; Friis et al., 2003; Nga et al., 2009; Rajagopal, Hotez, & Bundy, 2014; Taylor, Jinabhai, Kleinschmidt, & Jogessar, 2001). In addition, water and sanitation measures may be implemented with mass deworming to reduce exposure and transmission of infections.

2.3 How the intervention might work

Even with heavy infections, the nutritional requirements of intestinal worms relative to their human hosts are small. The harm to child welfare is expected to be caused by three factors: (a) malabsorption, (b) tissue damage and bleeding and (c) loss of appetite (Crawley, 2004). STH infections may cause malabsorption of nutrients in their hosts because of damage to the gastrointestinal surfaces. Hookworm infections are associated with anaemia, thought to be due to hookworm feeding on host tissue and to bleeding when they move from one site to another (Hall et al., 2008). Intestinal infections may also lead to reduced appetite which may negatively influence both growth and attention in school.

Deworming drugs are over 90% effective at reducing the worm load in individuals and are expected to reduce the prevalence of worm infection in the community as well as the intensity of infection in individuals (Figure 1). Reducing the prevalence and intensity of infection is expected to improve child nutritional status due to the mechanisms described above of reducing blood loss, reducing damage to gastrointestinal surfaces and improving appetite. Improved nutritional status and appetite are expected to improve attention in school and cognitive outcomes. Some have argued that deworming alone is insufficient to improve child health outcomes since the nutritional deficiencies caused by infections must be corrected with food and/or micronutrients (Hall et al., 2008).

Many potential effect modifiers have been described in the literature. Younger children may have a greater impact of deworming since they are smaller in size and the impact of infections may be greater on them (Hall et al., 2008). Girls may benefit less from deworming if they have lower school attendance (thus, not receiving deworming given at school) and if there is preferential distribution of food or other resources at home which could influence child welfare. Children who are stunted for age at three years of age may not be able to benefit as much in terms of growth. Conversely, children who are underweight may benefit more from deworming than those of normal weight (Hall et al., 2008). It is expected that benefits of deworming would only accrue to those who are infected, and even more so to those with heavier infection intensity (Hall et al., 2008). Low socioeconomic status is expected to be correlated with other features such as exposure to repeat intestinal infections, including those that cause diarrhoea, and thus children with lower socioeconomic status may not achieve as much benefit as less poor children.

Reinfection is expected to depend on the prevalence and intensity of infection as well as environmental factors such as the water and sanitation environment and hygiene practices in the community.
2.4 Why it is important to do the review

A recent Campbell systematic review and network meta-analysis (NMA) by members of our team (V. W., P. T., G. A. W., E. G., Z. B.), with 47 randomised trials and >1 million children, found little to no overall effect on growth, attention and school attendance (Welch et al., 2016). With NMA, we were able to explore the size of effect with different types and frequency of drugs and their combination with food or micronutrients; none of which contributed to larger effects. Our review also did not find larger effects in subgroups of children at the aggregate level across characteristics such as age, baseline nutritional status, prevalence or intensity of infection that have been postulated to be important (Welch et al., 2016). These analyses were conducted at the study level, rather than using data for each individual child, which limits the power to detect effect modification by individual participant characteristics. This review was therefore unable to identify whether mass deworming was more effective for children with certain characteristics. There was substantial unexplained heterogeneity between studies, with some studies finding larger effects than others, and no single individual-level, setting-level or methodology characteristic explaining this variation. Thus, we concluded that our analysis of effect modifiers was limited by the aggregate level data.

Our previous review was conducted using NMA, which allowed the comparison of treatments which had not been directly compared in head-to-head trials. NMA also allowed for the assessment of the role of multicomponent interventions (such as deworming combined with other parasite control interventions, food or micronutrients). Because there are several drugs used for mass deworming, this allowed the assessment of heterogeneity related to the type of drug, frequency and use of concomitant interventions.

IPD meta-analysis has been called the “gold standard” in meta-analyses for exploring individual level characteristics and their association with effects (Stewart, 1995). Advantages of IPD meta-analysis include improving data quality, enabling standardisation of outcomes, clarifying risk of bias and increasing the power to assess the interaction of participant characteristics with effect size (Dagne, Brown, Howe, Kellam, & Liu, 2016; Stewart et al., 2015). Furthermore, IPD analysis can explore the size and direction of differences in effect, thus assisting whether there is...
a greater benefit for some participants (Early Breast Cancer Trialists’ Collaborative Group, 1990). Another advantage of IPD is that they usually require an international collaborative effort, involving trial authors, who may help to identify more relevant trials, and also contribute to an agreed analysis plan and shared understanding of the results.

While failure to obtain some datasets may lead to selection bias if there are systematic reasons why some studies do not provide full data, methods have been developed to combine IPD with aggregate data (when IPD is not available for some studies) in NMA (Donegan, Williamson, D’Alessandro, & Smith, 2012; Sutton, Kendrick, & Coupland, 2008).

We decided in collaboration with several authors of primary trials that there would be value in conducting an IPD meta-analysis to explore the question of whether mass deworming is more effective for subgroups of children defined by characteristics such as infection intensity or status, age or nutritional status. This understanding could help to develop targeted strategies to reach these children better with deworming and guide policy regarding deworming.

3 | OBJECTIVES

The primary objective is to use IPD NMA to explore whether the effects of different types and frequency of deworming drugs as well as their combination with food or micronutrients on anaemia, cognition and growth vary with child-level and study-level characteristics (see Table 1), specifically: intensity of infection (as assessed by egg count), infection status (including species of worm), age, nutritional status, socioeconomic status and sanitation environment.

4 | METHODOLOGY

The protocol was registered with the Campbell Collaboration (Welch et al., 2018) and reported according to the preferred reporting items for systematic reviews and meta-analyses for protocols (PRISMA-P; Moher et al., 2015). Results of the review are reported using the PRISMA of individual patient data (PRISMA-IPD) Statement (Stewart et al., 2015) and the PRISMA for network meta-analyses (PRISMA-NMA).

4.1 | Criteria for including and excluding studies

We included studies which met the following eligibility criteria:

4.1.1 | Types of participants

Children aged 6 months up to 16 years. We excluded studies with <100 participants because of the time and effort required for each dataset and the information gained from smaller studies would be small compared to larger datasets. We did not exclude studies on the basis of attrition rate from the study.

4.1.2 | Types of interventions

Mass deworming using any drugs for STH or schistosomes with or without cointerventions such as food, micronutrients, iron or hygiene interventions. Eligible drugs include (but are not limited to) albendazole, praziquantel, levamisole, ivermectin, diethyl carbazine, pyrantel, piperaquine, metrifonate, hycanthone and tetramisole.

We included studies with combined approaches to parasite elimination such as albendazole and praziquantel. Also, because deworming may be used in combination with iron, food or hygiene promotion, we included studies with multiple component interventions.

Studies were included with placebo, control, or other active interventions (e.g., vitamin A, iron, hygiene promotion) as comparators.

As NMA depends on the assumption of transitivity (that participants could be randomised to any one of the treatments; Salanti, 2012), we planned to conduct two evidence networks of jointly randomizable interventions of drugs given for two indications. First, we assessed the evidence network of interventions given for STH which includes different frequencies of albendazole, mebendazole, levamisole, pyrantel, piperaquine, ivermectin and tetramisole with or without micronutrients or food. These are considered jointly randomizable because they are given for the same indication, and many have been compared in multiarm trials (Salanti, 2012).

4.1.3 | Types of study designs

We included randomised and quasirandomised trials. For the purpose of determining whether specific individual-level and environment-level characteristics are associated with greater effects of deworming, there is sufficient evidence from over 70 randomised trials with over 100,000 children to include only randomised and quasirandomised trials. We included studies reported in abstract form at a conference as well as unpublished studies. We sought full datasets from all studies and carried out the same methods for data checking and quality for all studies.

### TABLE 1 | Potential effect modifiers at child-level and environment level

| Child-level | Environment* |
|-------------|--------------|
| Age         | Population level prevalence |
| Sex         | Population level intensity |
| Nutritional status | Water and sanitation environment |
| Infection status | |
| Socioeconomic status | |
| Intensity of infection (including type of worm and duration of infection) | |

*Environment-level factors were not entered into the same model as individual-level modifiers because these factors are likely multicollinear. Instead, we planned to explore these factors with sensitivity analysis.
4.1.4 Types of outcome measures

The primary health outcomes were change from baseline in: weight (kg), height (cm), plasma ferritin, cognition and haemoglobin (g/L). We included studies which measured weight, haemoglobin, plasma ferritin, cognition or height. Cognition could be measured using scales that measured development (e.g., Raven’s matrices) or tests that assessed attention using digit recall.

We did not exclude on the basis of reported outcomes since some measured outcomes may not be reported in trial reports or abstracts.

We used the available data on age and sex to calculate height for age, weight for age and weight for height for children <5 years using the 2006 child growth standards (using WHO software Anthro version 3.2.2) and body mass index (BMI) for age for children aged five or older using the WHO Reference 2007 (using WHO AnthroPlus software).

Effects on infection intensity and status were assessed as secondary outcomes. Adverse effects of deworming were assessed in prior systematic reviews as minor and uncommon and the results are not contested, thus we did not assess adverse effects in this review.

Since the primary objective of this systematic review is to assess effect modification, particularly as it relates to infection status and intensity, we excluded studies that did not measure baseline infection prevalence of at least one of the STH or schistosomes.

4.1.5 Duration of follow-up

For weight and height, we included data from studies >4 months in duration because we considered this as a minimum duration to observe differences in growth based on clinical expertise of nutritionists on the team and decided a priori. However, for haemoglobin and ferritin status, changes may occur sooner, so study duration was not be used as an exclusion criterion. While infection status and infection intensity are affected much sooner than this, these are not primary outcomes of interest since there is no question that deworming drugs reduce infection load. We assessed infection intensity and status at baseline as indicators of the force of infection in the population. We collected data at each available time-point and aimed to explore study duration as a covariate in the model.

4.1.6 Types of settings

The settings included any area where STH or schistosomes were described as endemic.

4.2 Search strategy

We adapted the search strategy used for a previous Campbell review by members of our team (Welch et al., 2016) and updated the search to March 27, 2018. See search strategy in Appendix. We searched in the following databases: MEDLINE, CINAHL, LILACS, Embase, the Cochrane Library, Econlit, Internet Documents in Economics Access Service (IDEAS), Public Affairs Information Service (PAIS), Social Services Abstracts, Global Health CABI and CAB Abstracts.

We searched the System for Information on Grey Literature in Europe (SIGLE)-ended in 2005. We searched websites of relevant organisations such as the World Bank, World Food Program and International Food Policy Research Institute, as per the prior Campbell review (Welch et al., 2016).

We also contacted authors of studies and members of our advisory board for any unpublished studies or grey literature reporting eligible studies. We checked reference lists of relevant studies and reviews.

Titles and abstracts were screened in duplicate by two reviewers. We pilot-tested the screening criteria at both title and abstract screening stage and full text stage. We used the PRISMA flow diagram to report eligibility of studies. We retrieved full text of all studies which passed this first level screening. The full text review was also done in duplicate by two reviewers, and agreement was reached by consensus. Disagreements were resolved by consultation with a third reviewer. No language limits were applied. The research team had expertise in English, Portuguese, French and Spanish, and translation would have been sought if studies were found in other languages.

4.3 Description of methods used in primary research

Randomized controlled trials (RCTs) of deworming include two-arm trials as well as factorial trials, with children allocated either individually or by cluster-randomisation (e.g., by village or school).

4.4 Details of study coding categories

Details of the populations, interventions, comparators, outcomes and study design were extracted in duplicate by two reviewers, using a pretested form, designed for a previous Campbell review on deworming for children (Welch et al., 2016). This extraction includes details about the context, setting and environment, as well as sociodemographic details, and details about the frequency, delivery method and dose of interventions.

Two independent reviewers appraised each study with the Cochrane risk of bias tool which assesses selection bias, performance bias, detection bias, attrition bias and reporting bias (Cochrane Handbook; Higgins, Altman, & Sterne, 2011). Disagreements were resolved by discussion or consultation with a third reviewer.

We appraised the GRADE certainty for each outcome for each comparison by two independent reviewers, using the GRADE approach for NMA (Puhan et al., 2014). GRADE certainty (quality) "reflects our confidence that the estimates of the effect are correct. In the context of recommendations, quality reflects our confidence that the effect estimates are adequate to support a particular..."
recommendation. "Quality as used in GRADE means more than risk of bias and so may also be compromised by imprecision, inconsistency, indirectness of study results, and publication bias." (Bals hem et al., 2011). The two reviewers discussed ratings and reached consensus. Disagreements were resolved by consulting a third reviewer.

We developed a summary of findings table for each main comparison to show the effects for the outcomes of weight, height and haemoglobin, along with the quality of evidence (using GRADE certainty).

4.5 Statistical procedures and conventions

Data were prepared into a Microsoft Excel spreadsheet with the same fields for every study. Since we only included RCTs, we considered the missing values for each variable as missing at random (MAR) based on observed data (Joshi, Royuela, & Zamora, 2013).

We used multiple imputation to impute the missing values for baseline and outcome variables based on the assumption of MAR (Bell, Fiero, Horton, & Hu, 2014; Groenwold, Moons, & Vandenbroucke, 2014; Jakobsen, Gluud, Wetterslev, & Winkel, 2017) and created five complete datasets using Proc MI in SAS9.4/STAT (SAS Institute Inc., Cary, NC). All model estimates and standard errors were obtained by fitting the model to each of these five imputed datasets and aggregating results across them using Rubin’s Rule which incorporates uncertainty due to imputation. Proc MIANALYZE in SAS 9.4/STAT was used to obtain the aggregation of estimates across imputed datasets.

Descriptive characteristics of each study are presented, with details on the child characteristics, environment, worm species, prevalence, and intensity of infection, geographic location, interventions, comparator and outcomes and risk of bias assessment.

We accounted for clusters (such as villages, schools or households) as nested within each study.

We analysed IPD datasets to check for comparability with the primary published papers. We calculated the standardised difference between the published data and the IPD received from authors for baseline characteristics and baseline outcome assessment. For endpoint, we replicated the effect measures reported in study publications and calculated the standardised difference between the IPD received and the study report (Austin, 2009).

As with our previous Campbell review, we used a two-step process to meta-analysis. We conducted pairwise analyses for each comparison of interest by entering all IPD data into a multilevel model, with each study as one cluster. We expected considerable heterogeneity between studies for each outcome based on our Campbell review; therefore, we used a random effects model. We assessed mean differences in change from baseline for weight (kg), height (cm) and haemoglobin (g/L). We intended to assess plasma ferritin (mcg/L) but too few studies reported this outcome (seven studies with 6,318 participants). The Advisory board, based on clinical and methodological expertise, decided that there were insufficient studies to conduct effect modification analyses and that basic random effects meta-analysis could be misleading.

For cognition, we analysed measures of motor and cognitive development separately. We analysed measures of attention separately from developmental outcomes. We did not combine different measures of cognition.

We accounted for clustering as above by nesting clusters within studies. We decided on a set of predefined covariates with advice from our advisory board and coauthors. We accounted for the covariates of sex, age, infection intensity for each type of agent, socioeconomic status, maternal education and baseline nutritional status in the model. We assessed heterogeneity using visual inspection of forest plots for pairwise analyses as well as statistical tests of heterogeneity ($I^2$).

We conducted NMA with IPD, using a frequentist approach for random-effects NMA. The covariates were identified by the Study Advisory Group, namely: age, sex, baseline nutritional status (weight and height), haemoglobin and infection intensity. The effect estimate chosen was the mean difference for the continuous outcome of interest. The general linear mixed model (GLMM) follows a normal distribution using a mixed linear regression model. Random effect GLMM was conducted with two random effects considered in the model: random effect "trial" accounts for the response variables of patients within a given trial being correlated; and random effect "Patient’s clusters" which accounts for the correlation of responses between any two patients from the same clusters (such as villages, schools or households) within a given trial. We expected to have a connected network of trials to allow direct and indirect comparisons based on our Campbell review and NMA (see Figure 12, full evidence network for weight; Welch et al., 2016). We used the GLIMMIX procedure in SAS 9.4/STAT (SAS Institute Inc.) for the GLMM NMA, considering models that account for multiarm trials and adjust for the covariates identified. Results are summarised as point estimates with 95% confidence intervals (CIs).

4.6 Assessment of clinical and methodological heterogeneity within treatment comparisons

Within GLM, the explanatory model included covariates at the study level (e.g., methodological quality) and participant characteristics (anaemia, nutritional status, infection intensity, age, sex). We constructed forest plots for unadjusted direct treatment comparisons and adjusted treatment comparisons and assessed heterogeneity by visual inspection. Any study level or participant-level covariates that were statistically significant would have been analysed using subgroup analyses. We compared participant characteristics and trial methodology in tables.

4.7 Assessment of transitivity across treatment comparisons

Transitivity cannot be assessed statistically. With IPD, we have more opportunity to account for and model heterogeneity. As proposed by
Salanti (2012), we used IPD to assess the distribution of the child-level effect modifiers from Table 1 in each comparison to assess the plausibility of the transitivity assumption (Salanti, 2012). As above, transitivity is considered plausible since the treatments in each model (STH and schistosomiasis, respectively) are provided for the same indication and many of the treatments and their cointerventions have been included in multiarm trials (as shown by the prior review by our team: Welch et al., 2016).

4.8 | Assessment of statistical heterogeneity

For this IPD NMA, we assumed equal variances across comparisons within network. This assumption was tested using the Levene test.

4.9 | Assessment of statistical inconsistency

Inconsistency in an NMA is defined as a disagreement between the direct estimates (from direct comparisons of treatments) and indirect estimates (which are derived from the network comparisons). With GLMM we were unable to perform a test for model fit and consistency therefore we assessed underlying assumptions about consistency between indirect and direct evidence by comparing direct effect estimates with NMA effect estimates (direct and indirect evidence).

4.10 | Publication bias

A funnel plot would have been plotted for comparisons and outcomes with >10 studies. We used Egger’s test for asymmetry and visual inspection to assess the presence of publication bias and/or selective reporting in the entire corpus of randomised trials of deworming versus control for children (which includes some studies that were not eligible due to missing baseline data on infection intensity and some studies which were eligible but did not provide data).

We did not rank interventions because there is controversy as to the utility of ranking.

4.11 | Subgroup analyses

Provided sufficient data was available to inform the evidence network, subgroup analyses were conducted to assess effects across both child-level as well as environment-level characteristics. We compared the results of models with subgroup analyses by assessing the size of quantitative or qualitative differences in effects, the statistical significance of tests for interactions, assessing between-study variance and assessing the goodness of fit of the models using the likelihood ratio.

The following child and environment level effect modifiers were planned:

Child level:

- Individual-level intensity of infection with *ascaris*, *trichuris* and hookworm (across four levels of none, light, moderate and heavy, using the WHO cutoffs for each helminth (http://apps.who.int/iris/bitstream/10665/44671/1/9789241548267_eng.pdf)
- Stunting (HAZ> –2.0, HAZ < –2.0 to –3.0, HAZ < –3.0)
- Undernutrition (defined by WAZ cutoffs for children <5 years of age (http://apps.who.int/iris/bitstream/10665/44129/1/9789241598163_eng.pdf/ua=1) of WAZ > -2.0, WAZ < -2.0 to -3.0, WAZ < -3.0) and by BMI for age (BAZ) cutoffs for children aged 5 years or older available at http://www.who.int/growthref/who2007 bmi_for_age/en/) using BAZ > -2.0, BAZ < -2.0 to -3.0, BAZ < -3.0),
- Anaemia (using WHO cutoffs by age and altitude of nonanaemic, mild, moderate and severe, http://www.who.int/vmnis/indicators/hemoglobin.pdf)
- Age (<5 and ≥5 years of age)
- Sex (male/female)
- Socioeconomic status: socioeconomic status is measured in different ways in studies (e.g., questionnaires, asset indices, quintiles). We planned to assess whether the measurement of socioeconomic status could be compared across study settings and time. We decided this was not possible therefore we did not do a planned sensitivity analysis with children in the poorest tertile.

Before conducting subgroup analyses, we assessed the distribution of each variable. If there were insufficient children in some categories, the levels were combined (see results).

We planned to assess socioeconomic status of household or parents and maternal education as effect modifiers, but data was insufficient (see results).

Environment level:

- Study level sanitation and hygiene environment, as reported by parents and maternal education as effect modifiers, but data was insufficient (see results).
- Socioeconomic status could be compared across study settings and time. We decided this was not possible therefore we did not do a planned sensitivity analysis with children in the poorest tertile.

As noted in Table 1, environment level characteristics were not entered into the model. They were assessed by sensitivity analyses.

We expected poor reporting on these details in the articles based on our prior Campbell review, but some studies may have collected information on this at the study level that were not reported in the paper publications. We assessed whether there was sufficient data on the geographic location and date of the studies to assess study-level prevalence generated by the Global Atlas of Helminth Infections.

4.12 | Sensitivity analyses

Provided sufficient data was available to inform the evidence network, we conducted sensitivity analyses to assess robustness of results when restricted to studies at low risk of bias for sequence generation, allocation concealment and blinding of participants. We assessed whether results were robust to excluding imputed data (i.e.,
complete case analysis). We assessed sensitivity to restricting to studies published in 2008 or later (last 10 years).

Data were housed at a secure data warehouse at the Bruyère Research Institute, following the personal health information act. Data were transferred to SAS as a common platform for all studies, using a common data dictionary. V. W. checked IPD data for consistency immediately upon receiving datasets. For example, we checked for outlier individuals (e.g., with ages outside of eligibility criteria, duplicate participant IDs, unrealistic date ranges). We compared the IPD from authors with the aggregate data reported in the articles. Any missing or unusual data were flagged for discussion with the trial author or statistician by V. W. We asked for clarification from the authors to establish reasons for the errors, and corrected them if possible. Any requests for authors were discussed when the data was provided, such as clarification of trial risk of bias, conduct or eligibility criteria. We ran the same statistical analysis as the authors to check for consistency with the published paper (Stewart et al., 2015).

We requested statements of ethics approval from each study. No studies were identified that did not receive ethics approval. We requested that all data be transferred without any identifiers.

4.13 | Treatment of qualitative research

We did not include qualitative research.

5 | RESULTS

The results of this review are reported according to the PRISMA-IPD and PRISMA-NMA reporting guidelines (checklists in Table S1).

5.1 | Search results

We searched all databases up to March 27, 2018. We also retrieved in full text all 299 primary studies included in eight previous reviews (Danso-Appiah, Olliaro, Donegan, Sinclair, & Utzinger, 2013; Grimes et al., 2014; Kramer, Zhang, Sinclair, & Olliaro, 2014; Salam, Haider, Humayun, & Bhatta, 2015; Salam, Maredia, Das, Lassi, & Bhatta, 2014; Strunz et al., 2014; Taylor-Robinson et al., 2015; Welch et al., 2016).

We screened 14,034 records for inclusion. We screened 340 studies in full-text. We assessed 41 studies of deworming for STH and 14 studies of schistosomiasis treatment as eligible for inclusion. One study included treatments for both STH and schistosomiasis (Olds et al., 1999), and is included in both counts (Figure 2).

A total of 285 studies were excluded because they did not meet eligibility criteria, due to lack of infection intensity data (n = 14), < 3 months (n = 9) and wrong study design (n = 262; Table S3). We identified one ongoing study of albendazole (Table S4).

5.2 | Contacting authors and yield of studies

We contacted first authors of all eligible studies by email outlining the study purpose and inviting them to join the Deworming Collaborative. If there was no reply, contact with all authors was then made by email or using other contact information such as Researchgate and twitter. Authors were contacted in their language if possible (French, Portuguese).

For STH, we received complete data from 19 out of 41 published studies (46%) (Tables S5), which represented 79% of all children included in those eligible STH trials (Figure 3).

The retrieval of data was better for studies conducted after 2000, with a yield of 15 out of 22 published studies (68%) and 90% of participants randomised to eligible studies (Figure 4).

For studies conducted before 2000, we received only four out of 19 studies (21%), and 39% of participants randomised (Figure 5).

For schistosomiasis, we received data from only two out of 14 studies (14%) (Table S6), representing 37% of participants randomised to eligible studies (Figure 6). We decided not to pursue an analysis of schistosomiasis studies because of the risk of misleading results with an inadequate representation of available studies.

All study authors who provided data signed a data transfer agreement (Appendix 2).

5.3 | Characteristics of studies

5.3.1 | Studies contributing data: Settings, participants, size of studies

The 19 studies which provided data were conducted in Tanzania (Beasley et al., 1999; Beasley, 1995; Stoltzfus et al., 1997, 2004), Sri Lanka (Ebenezer et al., 2013), Kenya (Friis et al., 2003; Miguel & Kremer, 2004; Olds et al., 1999), Vietnam (Hall, Hanh, Farley, Quynh and Valdivia, 2006, Le Huong, Brouwer, Nguyen, Burema & Kok, 2007; Nga et al., 2009), China (Liu et al., 2017; Yap et al., 2014), Cote d’Ivoire (Rohner et al., 2010), Bangladesh (Rousham and Mascie-Taylor, 1994), Indonesia (Wiria et al., 2013), Nigeria (Kirwan et al., 2009), Uganda (Ndibazza et al., 2012) and the Philippines (Solon et al., 2003) (Tables 2 and S7).

Three of these studies were screen and treat (SAT) studies: Yap et al. (2014), Beasley et al. (1999) and Beasley (1995). We decided to include these in the model since our model is designed to adjust for infection intensity.

Seven studies were cluster RCTs, with the unit of randomisation as the household (Stoltzfus et al., 2004; Wiria et al., 2013), the village (Liu et al., 2017), and school (Ebenezer et al., 2013; Hall et al., 2006; Miguel & Kremer, 2004; Stoltzfus et al., 1997). The study duration ranged from 4 to 45 months. The median sample size was 486 (range, 124–15,881). Interventions included albendazole, mebendazole, praziquantel at different frequencies, iron supplements, micronutrient tablets and food (noodles or biscuits only) or beverages fortified with micronutrient and/or iron. The median frequency of deworming was every 4 months (range, 2–8 months).
FIGURE 2  PRISMA flow diagram. *Number of STH studies and schistosomiasis studies adds to 56 (not 55 as in the figure) since one study (Olds et al., 1999) is counted as both STH deworming and schistosomiasis deworming because it is a factorial trial. STH, soil-transmitted helminthiasis

FIGURE 3  Yield of STH studies and participants. STH, soil-transmitted helminthiasis
The median age of children in the studies was 10.8 years of age at enrolment (interquartile range, 8.8–13.0) according to IPD. For nutritional status, 16% of the children included in these studies were below −2 for BMI for age, 33% were stunted and 50% were anaemic (Table 3). The prevalence of infection was 45% for *A. lumbricoides* (31% light infections <4,999 eggs per gram of stool [egp], 13% moderate infection intensity from 5,000 to 49,999 egp and 1% heavy infection intensity with >49,999 egp), 52% for *T. trichiura* (38% light intensity <1,000 egp, 14% moderate between 1,000 and 9,999 egp and 0% heavy >10,000 egp) and 45% for hookworm (38% light intensity <2,000 egp, 5% moderate between 2,000 and 3,999 egp and 2% heavy >4,000 egp).

Additional child and setting characteristics for the 19 studies with <50% missing data are in Table S2.

### 5.3.2 Characteristics of STH deworming studies which did not provide data

Characteristics of studies that did not provide data are shown in Table S8. The main difference in these studies is their year of publication since we were more successful at obtaining data from more recent studies.
| Study            | Country      | Design      | Type of cluster (number of clusters) | Sample size (number of children per cluster) | Age (years) | Interventions                                                                 | Frequency, how often dewormed | Duration | Compliance with STH deworming                                                                 |
|-----------------|--------------|-------------|--------------------------------------|-----------------------------------------------|-------------|-------------------------------------------------------------------------------|--------------------------------|----------|-------------------------------------------------------------------------------------------|
| Beasley et al.  | Tanzania     | RCT SAT     | SAT                                  | 357                                           | 7–12        | 1. Albendazole + praziquantel  
2. Placebo                          | 5 months                        | 5 months | Not reported                                                                 |
| Beasley (1995)  | Tanzania     | RCT SAT     | SAT                                  | 217                                           | 6–15        | 1. Albendazole + praziquantel + iron  
2. Placebo                          | 4 months                        | 4 months | 100% (full course of 10 doses of iron given on a daily basis was received over 4 weeks due to absenteeism) |
| Ebenezer        | Sri Lanka    | cRCT MDA    | Schools (100)                         | 1,570 (20)                                    | 9.5         | 1. Mebendazole + iron tablet  
2. Placebo                          | 6 months                        | 6 months | 94–98% with deworming, 80% with iron tablets                                  |
| Friis (2003)    | Kenya        | RCT MDA     |                                       | 915                                           | 8–18        | 1. Albendazole + praziquantel  
2. Albendazole + praziquantel + micronutrient tablet  
3. Micronutrient tablet  
4. Placebo                          | 8 months                        | 8 months | Not reported                                                                 |
| Huong (2007)    | Vietnam      | RCT MDA     |                                       | 426                                           | 7.2         | 1. Mebendazole + unfortified noodles  
2. Mebendazole + iron fortified noodles  
3. Mebendazole + iron tablet  
4. Iron-fortified noodles  
5. Placebo + unfortified noodles | 3 months                        | 6 months | 93–99% consumed noodles and iron tablets                                      |
| Liu (2017)      | China        | cRCT MDA    | Townships (112)                       | 2,179 (20)                                    | 10.6        | 1. Albendazole  
2. Control (no deworming)                          | 6 months                        | 12 months | 52% fully compliant, 76% took at least one out of two albendazole pills in both rounds |
| Ndibazza et al. | Uganda       | RCT MDA     |                                       | 2,016                                         | 1.52        | 1. Albendazole  
2. Placebo                          | 3 months                        | 45 months | 19–22% received all 16 doses (over 5 years)                                   |
| Nga (2009)      | Vietnam      | RCT MDA     |                                       | 510                                            | 6–8         | 1. Albendazole + unfortified biscuit  
2. Albendazole + micronutrient fortified biscuit  
3. Micronutrient fortified biscuit  
4. Placebo + unfortified biscuit | 4 months                        | 4 months | 94% compliant with consuming biscuits                                          |
| Olds (1999)     | Kenya        | RCT MDA     |                                       | 371                                            | 10.5        | 1. Albendazole  
2. Praziquantel  
3. Albendazole + praziquantel  
4. Placebo                          | 6 months                        | 12 months | Not reported                                                                 |
| Rohner (2010)   | Cote d'Ivoire| RCT MDA     |                                       | 311                                            | 6–14        | 1. Iron fortified biscuits  
2. Albendazole + praziquantel  
3. IPT  
4. Albendazole + praziquantel + iron fortified biscuits | 3 months                        | 6 months | 94% for anthelminthics                                                        |

(Continues)
| Study          | Country       | Design  | Type of cluster (number of clusters) | Sample size (number of children per cluster) | Age (years) | Interventions                                                                 | Frequency, how often dewormed | Duration | Compliance with STH deworming |
|---------------|---------------|---------|-------------------------------------|---------------------------------------------|-------------|--------------------------------------------------------------------------------|--------------------------------|----------|-----------------------------|
| Solon (2003)  | Philippines   | RCT MDA |                                     | 831                                         | 9.9         | 1. Albendazole + unfortified beverage  
2. Albendazole + micronutrient fortified beverage  
3. Micronutrient fortified beverage  
4. Placebo + unfortified beverage                                           | 4 months                     | 4 months                  | Not reported                |
| Stoltzfus et al. (1997) | Tanzania cRCT | Schools (12) | 4,034                              | 10.5                                        | 1. Mebendazole (2/year)  
2. Mebendazole (3/year)  
3. Placebo                                                                                   | 6 months                     | 4 months                  | 12 months                  | Not reported |
| Stoltzfus et al. (2004) | Tanzania cRCT | Households (451) | 463                              | 6–59 months                                    | 1. Mebendazole (high)  
2. Mebendazole (high) + iron supplement  
3. Iron supplement  
4. Placebo                                                                        | 3 months                     | 12 months                  | Not reported                |
| Yap (2014)    | China         | RCT SAT |                                     | 194                                         | 9–12        | 1. Albendazole  
2. Placebo                                                                            | 6 months                     | 6 months                  | 92%, field investigators directly observed consumption |
| Kirwan (2009) | Nigeria       | RCT MDA |                                     | 1,367                                       | 1–4         | 1. Albendazole  
2. Placebo                                                                            | 4 months                     | 14 months                  | Not reported. Consumption was directly observed |
| Hall (2006)   | Vietnam       | cRCT MDA | Schools (80)                        | 2,916                                       | 6.8         | 1. Albendazole + vitamin A  
2. Placebo + vitamin A                                                                   | 6 months                     | 12 months                  | Not reported                |
| Miguel (2004) | Kenya         | cRCT MDA | Schools (75)                        | 15,881                                      | 6–18        | 1. Albendazole  
2. Albendazole + praziquantel  
3. Control                                                                                         | 3 months                     | 3 months                  | 96%                          |
| Rousham (1994) | Bangladesh cRCT MDA | Villages (7) | 124                              | 2–6                                         | 1. Mebendazole  
2. Placebo                                                                          | 2 months                     | 12 months                  | Not reported                |
| Wiria (2013)  | Indonesia     | cRCT MDA | Households (954)                    | 1,854                                       | 2–16        | 1. Albendazole  
2. Placebo                                                                          | 3 months                     | 21 months                  | 78% with anthelmintic        |

Abbreviation: MDA, mass drug administration; RCT, randomized controlled trial; SAT, screen and treat; STH, soil-transmitted helminthiasis.

*Of 4004 people randomized, only 1854 met our age range (6 months to 16 years), and of those 1854, only 738 had baseline data for weight and height.
### TABLE 3  Characteristics of studies with <50% missing data which were included in the main model

| Variable and subgroups | Beasley 99 | Beasley TAN | Ebenezer | Fris | Huong | Liu | Olds 1999 | Rohner | Solon | Stolfuz 2004 | Stolfuz 1997 | Yap | Ndibazza | Sample size |
|------------------------|-----------|-------------|----------|------|-------|----|----------|--------|-------|-------------|-------------|-----|----------|-------------|
| **BMI for age (z score)** |           |             |          |      |       |    |          |        |       |              |              |     |          |              |
| <−2 (≤−2)              | 16        | 17          | 626      | 77   | 102   | 141| 62       | 41     | 1    | 146         | 12          | 5   | 66       | 2,254       |
| <−2                    | 339       | 200         | 945      | 838  | 324   | 2038| 448      | 330    | 293  | 685         | 451         | 189 | 1,950    | 11,695      |
| ≥−2 (<2)               | 355       | 217         | 1,571    | 915  | 426   | 2,179| 510      | 371    | 310  | 831         | 463         | 3,591 | 194      | 2,016       |
| **Height for age (z score)** |           |             |          |      |       |    |          |        |       |              |              |     |          |              |
| <−2 (≤−2)              | 162       | 67          | 462      | 124  | 129   | 607 | 143      | 102    | 76   | 329         | 221         | 1,771 | 113      | 4,605       |
| <−2                    | 193       | 150         | 1,109    | 791  | 297   | 1,572| 367      | 269    | 234  | 502         | 242         | 1,820 | 81       | 9,344       |
| ≥−2 (<2)               | 355       | 217         | 1,571    | 915  | 426   | 2,179| 510      | 371    | 310  | 831         | 463         | 3,591 | 194      | 2,016       |
| **Hookworm (epg)**     |           |             |          |      |       |    |          |        |       |              |              |     |          |              |
| 0-384                  | 30        | 35          | 1,379    | 411  | 388   | 2,162| 483      | 49     | 135  | 625         | 205         | 214 | 75       | 1,514       |
| 1-1,776                | 85        | 70          | 107      | 451  | 21    | 17   | 3        | 176    | 141  | 206         | 256         | 1,034 | 98       | 3,166       |
| >1,776                 | 242       | 112         | 85       | 53   | 17    | 24   | 146      | 35     | 2    | 2,346       | 21          | 1    | 1        | 3,084       |
| **Trichuris trichiura (epg)** |           |             |          |      |       |    |          |        |       |              |              |     |          |              |
| 0-384                  | 103       | 118         | 1,368    | 499  | 113   | 1,661| 236      | 79     | 283  | 528         | 126         | 136 | 11       | 6,733       |
| 1-1,776                | 131       | 62          | 168      | 376  | 87    | 497  | 143      | 172    | 27   | 301         | 325         | 736 | 94       | 3,661       |
| >1,776                 | 123       | 37          | 35       | 40   | 226   | 21   | 131      | 120    | 1    | 2           | 12          | 2,722 | 89       | 3,561       |
| **Ascaris lumbricoides (epg)** |           |             |          |      |       |    |          |        |       |              |              |     |          |              |
| 0-384                  | 175       | 188         | 1,157    | 788  | 138   | 1,508| 183      | 244    | 284  | 385         | 253         | 959 | 13       | 7,737       |
| 1-1,776                | 11        | 6           | 145      | 50   | 21    | 621  | 19       | 45     | 26   | 363         | 209         | 1,175 | 15       | 3,126       |
| >1,776                 | 171       | 23          | 269      | 77   | 267   | 50   | 308      | 82     | 1    | 83          | 1           | 1,460 | 166      | 3,092       |
| **Anyworm (epg)**      |           |             |          |      |       |    |          |        |       |              |              |     |          |              |
| 0                      | 1,077     | 217         | 50       | 2,168| 101   | 129 | 306      | 88     | 12   | 1,448       | 4,719       |     |          |              |
| 1                      | 173       | 164         | 291      | 639  | 111   | 902 | 184      | 233    | 179  | 514         | 375         | 1,682 | 35       | 6,045       |
| 2                      | 184       | 53          | 203      | 59   | 265   | 9    | 225      | 115    | 3    | 11          | 1,900       | 159 | 5        | 3,191       |
| **Anaemia**            |           |             |          |      |       |    |          |        |       |              |              |     |          |              |
| No                     | 247       | 132         | 347      | 299  | 53    | 361 | 127      | 264    | 214  | 318         | 440         | 2,785 | 13       | 6,980       |
| Yes                    | 110       | 85          | 1,224    | 616  | 373   | 1,818| 383      | 107    | 97   | 513         | 23          | 809  | 181      | 6,975       |
| **Age**                |           |             |          |      |       |    |          |        |       |              |              |     |          |              |
| <5 years               | 355       | 137         | 1,571    | 915  | 426   | 2,179| 510      | 371    | 311  | 831         | 463         | 3,594 | 194      | 2,016       |
| >5 years               | 355       | 137         | 1,571    | 915  | 426   | 2,179| 510      | 371    | 311  | 831         | 460         | 3,594 | 194      | 2,016       |
| **Sex**                |           |             |          |      |       |    |          |        |       |              |              |     |          |              |
| Male                   | 204       | 71          | 812      | 447  | 211   | 1,173| 243      | 219    | 184  | 434         | 246         | 1,864 | 94       | 1,041       |
| Female                 | 153       | 66          | 759      | 468  | 215   | 1,006| 267      | 152    | 127  | 387         | 217         | 1,730 | 100      | 6,622       |

Abbreviations: epg, eggs per gram of stool; STH, soil-transmitted helminthiasis.

**“Anyworm”** is a variable indicating children with no detected STH infection of any type of STH, light intensity using WHO cut-offs for each type of STH, or moderate or heavy infection intensity for any type of STH.

**Anaemia cut points defined on the basis of age and sex using WHO guidelines.**
5.3.3 | Compared to the 2016 aggregate data Campbell review

Seventeen studies which were included in our prior Campbell review (Welch et al., 2016) were excluded because they were not randomised or quasirandomised trials (n = 2), had no baseline infection intensity data (n = 15). These studies are summarised in Table S9.

5.3.4 | Aggregate effect estimates of studies not providing IPD

We compared the effect estimates of the studies which were eligible but did not provide data, those that provided data and those which were not eligible (no infection intensity, too small or too short).

Results for STH deworming versus placebo for weight gain (kg) are shown in Figure 7. As can be seen on visual inspection, two studies had much larger effects on weight gain than any others (Stephenson, Latham, Adams, Kinoti, & Pertet, 1993; Stephenson, Latham, Kurz, Kinoti, & Brigham, 1989). The heterogeneity with both of these studies included was 90% as assessed by $I^2$, suggesting that statistical combining of these studies is inappropriate. As in our previous Campbell review, we removed outliers to assess contribution to $I^2$.

Removing Stephenson (1989), which we earlier assessed as having imbalance in baseline covariates which may have influenced results (Welch et al., 2016), resulted in an $I^2$ of 71%, which we considered acceptable for statistical pooling, following the Cochrane Handbook guidance (Higgins et al., 2011). The test for interaction of effect was not statistically significant ($p = .10$).

Details for height and haemoglobin for STH versus placebo are shown in Appendix 3, comparison 1. The interaction test for subgroup effects was not statistically significant for any of these outcomes. However, the studies which were not included were older (with 8/16 published before 2000) compared to the studies which provided IPD (3/13 post-2000). Also, the size of effect was larger for studies which did not provide IPD or

**FIGURE 7** Weight gain (kg) for STH versus placebo for studies providing IPD and studies not included in the IPD analysis. IPD, individual participant data; STH, soil-transmitted helminthiasis.
were not eligible for weight gain with an effect of 0.07 kg (95% CI: 0.01, 0.13).

5.4 | Feasibility of conducting IPD meta-analysis

We judged that we had insufficient data to conduct analysis of the studies of deworming for schistosomiasis since we received only two studies out of 13 eligible for analysis, and this represented 36% of participants randomised to eligible studies.

For deworming for STH, we received IPD from 19 studies out of 41 considered eligible (46%) and 31,945 out of 40,525 participants randomised (79%). We considered this was sufficient data to pursue IPD meta-analysis.

5.5 | Quality of studies

Overall, there was low risk of selection and performance bias in 47% (9 of 19) studies. 47% (9 studies) had unclear risk of bias due to lack of detail on allocation method or method of blinding. Overall, there was a high risk of attrition bias in 37% (seven studies) of the included studies. Attrition bias was judged high risk due to loss to follow-up of >20% of participants in these studies. Detection bias could not be assessed in 58% (11 studies) of the studies and selective reporting could not be assessed in 79% (15 studies) due to insufficient information. No major baseline imbalance was found in 74% (14 studies) of the studies, judged according to the description of baseline characteristics (Figures 8 and 9).

The overall risk of bias was similar for studies for which we were unable to obtain data except for selection bias which was low risk in only 4.5% (1 of 22 studies) and unclear in 91% (22 studies) and blinding of personnel which was low risk in 18% (four studies) and unclear in 72% (16 studies) due to lack of description of the method of allocation or blinding (Figures 10 and 11).

5.6 | Preparation, replication, imputation, measurement and estimation

As described in the methods, we followed four steps to prepare, replicate, impute and calculate anthropometric Z scores.
5.6.1 Preparation: missingness analysis

Of the 19 studies that met this review’s inclusion criteria, 14 studies were missing <50% of data for outcomes and covariates at baseline and endline, and were included in the main analysis (Table 4). For the studies included in the main analysis, there was an average of 4% missing data at baseline (range, 0–42%), and an average of 9% missing data at endline (range, 0–31%). Five studies (Hall et al., 2006; Kirwan et al., 2009; Miguel & Kremer, 2004; Rousham & Mascie-Taylor, 1994; Wiria et al., 2013) were missing more than 50% of outcome or covariate data at baseline or endline, and were included in the complete case analysis only. Wiria et al. (2013), Hall et al. (2006), and Miguel and Kremer (2004) were missing more than 50% of data for all STH counts at baseline. Hall et al. (2006) and Rousham and Mascie-Taylor (1994) did not collect haemoglobin at baseline nor endline. Wiria et al. (2013) and Kirwan et al. (2009) were missing more than 50% of data on all outcome variables at endline. Miguel and Kremer (2004) was missing height measures for all study participants at baseline, and haemoglobin measures for all participants at endline.

5.6.2 Replication

Replication of the published study results was conducted for all 19 eligible studies. The standardised differences between the published and replication results were at or below 0.10 for all outcome measures and covariates at baseline and endline, with the exception of two measures from the Ebenezer et al. (2013) study (baseline haemoglobin and baseline age) (Table 5). The average standardised difference between published study results and replication results at baseline and endline were 0.014 (range, −0.13–0.15) and 0.015 (range, −0.09–0.07), respectively. For every study, there was at least one instance where the standardised difference could not be calculated at baseline or endline because the published results did not report the covariate or outcome measure in question (indicated as "NA" in Table 6).

5.6.3 Imputation

We used multiple imputation for missing data at baseline and endline and created five completed datasets.
| Studies                  | Baseline |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|-------------------------|----------|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|                        | N        | Age (%) | Sex (%) | Ascaris lumbricoides epg (%) | Trichuris trichiura epg (%) | Hookworm epg (%) | Hb (%) | Weight (%) | Height (%) | Hb (%) | Weight (%) | Height (%) |
| Ebenezer (2013)         | 1,579    | 48 (3.0) | 26 (1.6) | 114 (7.2) | 114 (7.2) | 114 (7.2) | 50 (3.2) | 9 (0.6) | 9 (0.6)    | 207 (13.1) | 219 (13.9) | 205 (13.0) |
| Friis (2003)            | 915      | 0      | 0      | 0      | 0      | 0      | 212 (23.2) | 134 (14.6) | 133 (14.5) | 282 (30.8) | 224 (24.5) | 222 (24.3) |
| Huong (2007)            | 426      | 0      | 8 (0.2) | 0      | 0      | 0      | 0      | 0 | 0         | 0          | 16 (3.8) | 16 (3.8) | 16 (3.8) |
| Liu et al. (2017)       | 2,180    | 1 (0.0) | 1 (0.0) | 610 (28.0) | 573 (26.3) | 905 (41.5) | 1 (0.0) | 2 (0.0) | 2 (0.0)    | 139 (6.4) | 134 (6.1) | 134 (6.1) |
| Nga (2009)              | 510      | 0      | 0      | 0      | 0      | 0      | 0      | 0 | 0         | 0          | 38 (7.5) | 28 (5.5) | 28 (5.5) |
| Olds (1999)             | 371      | 0      | 0      | 0      | 0      | 0      | 0      | 0 | 0         | 0          | 44 (11.9) | 44 (11.9) | 44 (11.9) |
| Rohner (2010)           | 635      | 130 (20.5) | 46 (7.2) | 45 (7.1) | 45 (7.1) | 44 (6.9) | 24 (3.8) | 27 (4.3) | 81 (12.8) | 84 (13.2) | 2 (0.3) |
| Solon (2003)            | 831      | 0      | 0      | 159 (19.1) | 159 (19.1) | 159 (19.1) | 28 (3.4) | 0 | 0         | 0          | 28 (3.4) | 0 | 0 |
| Yap (2014)              | 194      | 0      | 0      | 0      | 0      | 0      | 0      | 0 | 0         | 0          | 0 | 0 |
| Beasley et al. (1999)   | 357      | 0      | 0      | 0      | 0      | 0      | 0      | 0 | 1 (0.0)   | 1 (0.0)    | 56 (15.7) | 56 (15.7) | 56 (15.7) |
| Beasley Tanbase         | 217      | 0      | 0      | 0      | 0      | 0      | 0      | 0 | 9 (4.1)   | 5 (2.3)    | 5 (2.3) | 24 (11.1) | 24 (11.1) |
| Stoltzfus (1997)        | 4,034    | 440 (11.0) | 192 (4.8) | 598 (14.8) | 598 (14.8) | 597 (14.8) | 431 (10.7) | 432 (10.7) | 431 (10.7) | 719 (17.8) | 722 (17.9) | 723 (17.9) |
| Stoltzfus (2004)        | 463      | 0      | 0      | 15 (3.2) | 15 (3.2) | 15 (3.2) | 0      | 0 | 0         | 0          | 35 (7.6) | 35 (7.6) | 35 (7.6) |
| Ndibazza et al. (2012)  | 2,016    | 341 (16.9) | 0      | 534 (26.5) | 534 (26.5) | 534 (26.5) | 388 (19.2) | 343 (17.0) | 359 (17.8) | 449 (22.3) | 434 (21.5) | 448 (22.2) |
| Wiria (2013)            | 1,854    | 0      | 0      | 1,277 (68.9) | 1,041 (56.1) | 1,277 (68.9) | 1,629 (87.9) | 1,116 (60.2) | 1,116 (60.2) | 1,425 (76.9) | 1,186 (64.0) | 1,186 (64.0) |
| Kirwan (2009)           | 1,367    | 0      | 14 (0.01) | 102 (0.07) | 101 (0.07) | 100 (0.07) | 57 (0.04) | 9 (0.01) | 12 (0.01) | 953 (69.7) | 873 (63.9) | 883 (64.6) |
| Hall (2006)             | 2,916    | 256 (0.09) | 0      | 2,295 (78.7) | 2,295 (78.7) | 2,295 (78.7) | 2,916 (100.0) | 256 (0.09) | 256 (0.09) | 256 (0.09) | 256 (0.09) |
| Miguel (2004)           | 15,901   | 2,820 (17.7) | 2,771 (17.4) | 14,007 (88.1) | 14,007 (88.1) | 15,015 (94.4) | 14,007 (88.1) | 14,007 (88.1) | 15,901 (100) | 15,901 (100) | 15,901 (100) |
| Rousham (1994)          | 124      | 1 (0.01) | 1 (0.01) | 29 (23.4) | 29 (23.4) | 29 (23.4) | 124 (100.0) | 2 (0.02) | 3 (0.02) | 124 (100.0) | 6 (0.05) | 6 (0.05) |
Measurement and estimation

Two studies (Ebenezer et al., 2013 and Yap et al., 2014) required adjustments to haemoglobin measures due to high altitude. The altitude correction method applied was:

$$Hb_{\text{sea level}} = Hb_{\text{measured}} - 3.44 \times (e^{-0.633 \times \text{Alt}}) - 1),$$

where $Hb_{\text{sea level}}$ stands for the concentration after adjustment, and Alt for altitude (m) (Dirren, Logman, Barclay, & Freire, 1994). The mean altitude for each village was applied to each child in the village.

BMI for age, weight for age and height for age were calculated as described above, using Anthro Software.

Distribution curves for effect modifier variables were prepared to confirm there were sufficient numbers of children in each pre-specified level to conduct subgroup analyses (Supporting Information Figures). For individual-level intensity of infection (any helminth, Ascaris, hookworm, Trichuris), the distribution curves showed that there were insufficient numbers of children with a high intensity level of any helminth infection to justify the use of the WHO cutoffs for each helminth, as originally planned. Consequently, tertiles for the distributions were calculated and used to define the levels of the subgroup analyses to assess the gradient of effect for each helminth and for infection intensity (any helminth). The cutoffs used for BMI-for-age $z$ score, weight-for-age $z$ score, and height-for-age $z$ scores were adjusted to include only two levels ($\leq -2SD$, $> -2SD$) to accommodate the lack of children with extreme scores at either end of the distribution. Anaemia status was adjusted to two levels (not anaemic, anaemic) for the same reason.

### Table 5

| Studies                      | Hb  | Weight | Height | Age  | Sex | Ascaris lumbricoides epg | Hookworm epg | Trichuris trichiura epg |
|------------------------------|-----|--------|--------|------|-----|--------------------------|--------------|-------------------------|
| Beasley et al. (1999)        | 0.00| NA     | NA     | NA   | NA  | 0.00                     | 0.00         | 0.00                    |
| Beasley Tanbase              | NA  | NA     | NA     | NA   | NA  | NA                       | NA           | NA                      |
| Ebenezer (2013)*             | 0.00| 0.15   | NA     | NA   | NA  | 0.00                     | 0.00         | NA                      |
| Friis (2003)                 | −0.06| 0.007  | −0.02, 0.025 | −0.05, 0.04 | 0.00, 0.004 | NA          | NA         | NA                      |
| Huang (2007)                 | −0.08, 0.02 | −0.10, 0.04 | −0.01, 0.00 | −0.02, 0.04 | NA          | NA         | NA                      |
| Liu et al. (2017)            | 0.00| 0.00   | 0.00   | 0.00 | 0.00 | 0.00                     | 0.00         | 0.00                    |
| Ndliba et al. (2012)         | NA  | NA     | NA     | 0.00 | 0.00 | NA                       | NA           | NA                      |
| Nga (2009)                   | 0.00, 0.01 | −0.01, 0.00 | −0.01, 0.01 | 0.00 | NA  | 0.00                     | NA           | NA                      |
| Olds (1999)                  | NA  | NA     | NA     | NA   | NA  | NA                       | NA           | NA                      |
| Rohner (2010)                | −0.02, 0.01 | 0.00         | 0.00   | −0.02, 0.02 | NA          | NA         | NA                      |
| Solen (2003)                 | −0.01, 0.00 | 0.00         | 0.00   | −0.02, 0.02 | NA          | NA         | NA                      |
| Stoltzfus (1997)             | NA  | 0.00   | 0.00   | 0.00 | 0.00 | 0.00                     | 0.00         | 0.00                    |
| Stoltzfus (2004)             | −0.08, 0.00 | 0.00         | −0.09, 0.03 | NA          | NA         | NA         | NA                      |
| Yap (2014)                   | −0.01, 0.02 | 0.00         | −0.01, 0.00 | −0.02, 0.03 | NA          | 0.00       | 0.00                    |
| Kirwan (2009)                | NA  | NA     | NA     | NA   | NA  | NA                       | NA           | NA                      |
| Hall (2006)                  | NA  | 0.00   | 0.00   | 0.00 | 0.00 | 0.00                     | 0.00         | 0.00                    |
| Miguel (2004)                | NA  | NA     | NA     | NA   | NA  | 0.00                     | 0.00         | 0.00                    |
| Rousham (1994)               | NA  | 0.00   | 0.00   | NA   | NA  | NA                       | NA           | NA                      |
| Wiria (2013)                 | NA  | 0.00   | 0.00   | NA   | NA  | NA                       | NA           | NA                      |

Abbreviation: epg, eggs per gram of stool.

*Standardised differences between published and reproduced results > 0.10.

5.6.4 Measurement and estimation

Two studies (Ebenezer et al., 2013 and Yap et al., 2014) required adjustments to haemoglobin measures due to high altitude. The altitude correction method applied was:

$$Hb_{\text{sea level}} = Hb_{\text{measured}} - 3.44 \times (e^{-0.633 \times \text{Alt}}) - 1),$$

where $Hb_{\text{sea level}}$ stands for the concentration after adjustment, and Alt for altitude (m) (Dirren, Logman, Barclay, & Freire, 1994). The mean altitude for each village was applied to each child in the village.

BMI for age, weight for age and height for age were calculated as described above, using Anthro Software.

Distribution curves for effect modifier variables were prepared to confirm there were sufficient numbers of children in each pre-specified level to conduct subgroup analyses (Supporting Information Figures). For individual-level intensity of infection (any helminth, Ascaris, hookworm, Trichuris), the distribution curves showed that there were insufficient numbers of children with a high intensity level of any helminth infection to justify the use of the WHO cutoffs for each helminth, as originally planned. Consequently, tertiles for the distributions were calculated and used to define the levels of the subgroup analyses to assess the gradient of effect for each helminth and for infection intensity (any helminth). The cutoffs used for BMI-for-age $z$ score, weight-for-age $z$ score, and height-for-age $z$ scores were adjusted to include only two levels ($\leq -2SD$, $> -2SD$) to accommodate the lack of children with extreme scores at either end of the distribution. Anaemia status was adjusted to two levels (not anaemic, anaemic) for the same reason.

5.7 Effect of deworming on infection intensity

The effect of deworming on infection intensity was assessed for each study and each type of STH infection and found to be variable across studies (see Appendix 4, Forest plots, comparisons 9 and 10). When sorted according to year of publication, there was no visual trend of greater infection prevalence between the years of publication of these studies from 1999 to 2015. The complete case analysis (only including children with complete data on infection prevalence) were comparable to results conducted using multiple imputation for baseline prevalence.

Six studies had relative risk reduction of $A.\ lumbricoides$ infection prevalence 20% or more when compared to the placebo group in $A.\ lumbricoides$ prevalence at endline (Beasley et al., 1999; Friis et al., 2003; Le Huang et al., 2007; Nga et al., 2009; Stoltzfus et al., 1997, 2004) and these were included in a sensitivity analysis to assess...
whether greater impact on *A. lumbricoides* prevalence was associated with greater effects on growth or haemoglobin.

One study did not assess endline infection intensity (Liu et al., 2017).

### 5.8 | NMA-IPD model development

We planned our analysis model *a priori* based on consultation with the advisory group and our research team to consider study design elements, outcomes, covariates and effect modifiers.

#### 5.8.1 | Changes to analysis model

The effect on plasma ferritin levels was not assessed because only seven studies measured this outcome (Beasley et al., 1999; Beasley, 1995; Le Huong et al., 2007; Nga et al., 2009; Rohner et al., 2010; Stoltzfus et al., 1997, 2004) (Table 7).

Six out of 14 studies (Ebenezer et al., 2013; Liu et al., 2017; Nga et al., 2009; Rohner et al., 2010; Solon et al., 2003; Stoltzfus et al., 1997) measured effects on cognition outcomes. However, the specific measures and methods used to assess cognition varied by study. At the December 2017 meeting of the review investigators and advisors (London, UK), it was decided to assess cognition (using measures for attention and development) on a study-by-study basis. Where measures were described with the same name (e.g., working memory in Liu et al., 2017; Ndibazza et al., 2012; Nga et al., 2009), the Advisory Group recommended not combining results across studies since the translation and different contexts of the studies could influence the tool’s application. Cognitive measures were categorised as related to: (a) short-term attention (e.g., digit recall), (b) scholastic performance (e.g., math, language tests) or (c) developmental outcomes (e.g. motor development, Raven’s index).

An insufficient number of eligible studies included measures for maternal education and socioeconomic status, and the specific measures used varied by study (Table 8). Five studies (Ebenezer et al., 2013; Liu et al., 2017; Ndibazza et al., 2012; Nga et al., 2009; Yap et al., 2014) included a measure for maternal education, and seven studies (Beasley et al., 1999; Beasley, 1995; Liu et al., 2017; Ebenezer et al., 2013; Ndibazza et al., 2012; Nga et al., 2009; Yap et al., 2014) included a measure for socioeconomic status. Given the limited number of studies and the variability in measures, these measures were not included as covariates in the model.

The weight-for-height z score for children under 5 years that was originally planned as a covariate was replaced by BMI-for-age on the recommendation of the Advisory Group to avoid collinearity between weight-for-age and height-for-age z scores.

Indicators for water and sanitation were not included as effect modifiers because not all studies described water and sanitation conditions (see Table 2—Characteristics of Included Studies). The studies that did provide descriptions did not do so in a quantifiable way that would allow comparison.

#### 5.8.2 | Evidence network and feasibility assessment for NMA

The full evidence network included 18 nodes (Figure 12) due to different types of deworming (e.g., albendazole, mebendazole and praziquantel), cointerventions (e.g., micronutrients) and frequency of deworming. We considered the control arm of two studies as equivalent to placebo (Liu and Miguel).

#### 5.9 | Evidence network refinement

We ran the NMA-IPD for the full network with 18 nodes, as above. We excluded five studies with >50% missing data since we could not impute missing data and adjusted analyses would be biased due to the amount of missing data. We decided to include these five studies in a “complete case” sensitivity analysis.

The results with the full evidence network were presented at a meeting of the Advisory Group in June 2017 (Table S13: full network —14 studies, 18 nodes). The Advisory Board decided that the full network was too complicated to allow meaningful interpretation for policy decisions.

The effects on weight gain, height gain and haemoglobin were not statistically significant for the two types of STH deworming drugs: albendazole and mebendazole. Since the WHO guidelines on deworming (WHO, 2017) do not distinguish between the choice of mebendazole or albendazole on the grounds of nutritional effects, the Advisory board decided to collapse across type of STH drug.

With respect to praziquantel, results showed larger effects on haemoglobin for all treatment comparisons which included...
praziquantel (e.g., Albendazole + praziquantel effect on haemoglobin was 2.03 g/L, 95% CI: 0.56, 3.50) compared to effect of albendazole and praziquantel (e.g., Albendazole + praziquantel effect on haemoglobin was 2.03 g/L, 95% CI: 0.56, 3.50) compared to effect of albendazole and praziquantel (e.g., Albendazole + praziquantel effect on haemoglobin was 2.03 g/L, 95% CI: 0.56, 3.50)

TABLE 7
Comparison of original analysis plan and actual model employed

| Planned | Actual |
|---------|--------|
| **Design** | **Study**<br>**Clusters**<br>**Treatment arms**<br>**Number of 6-month periods** | **Study**<br>**Clusters**<br>**Treatment arms** |
| **Outcomes**<br>**Change in weight (kg)**<br>**Change in height (cm)**<br>**Change in haemoglobin (g/L)**<br>**Change in cognition**<br>**Change in plasma ferritin** | **Change in weight (kg)**<br>**Change in height (cm)**<br>**Change in haemoglobin (g/L)**<br>**Change in cognition (by study only)** |
| **Covariates**<br>Age<br>Sex<br>Ascaris lumbricoides epg count<br>Hookworm epg count<br>Trichurus trichiura epg count<br>Haemoglobin<br>Height-for-age<br>BMi-for-age (5 years and older)<br>Weight-for-height (under 5 years)<br>Socioeconomic status | Age<br>Sex<br>A. lumbricoides epg count<br>Hookworm epg count<br>T. trichiura epg count<br>Haemoglobin<br>Height-for-age<br>BMi-for-age (all ages) |
| **Effect modifiers**<br>Weight-for-age z score (<−3SD, −3SD, −2SD, >2SD) <br>Height-for-age z score (<−3SD, −3SD, −2SD, >2SD) <br>A. lumbricoides intensity (0, light, moderate, heavy)<br>Hookworm intensity (0, light, moderate, heavy)<br>T. trichiura intensity (0, light, moderate, heavy)<br>Any helminth infection intensity (0, light, moderate, heavy)<br>Anaemia status (none, mild, moderate, severe)<br>Age (1–5, >5 years)<br>Sex (female, male) | BMi-for-age z score (<−2SD, >2SD)<br>Height-for-age z score (<−2SD, >2SD)<br>A. lumbricoides intensity (tertiles)<br>Hookworm intensity (tertiles)<br>T. trichiura intensity (tertiles)<br>Any helminth infection intensity (tertiles)<br>Anaemia status (not anaemic, anaemic)<br>Age (1–5, >5 years)<br>Sex (female, male) |

Abbreviation: BMI, body mass index; epg, eggs per gram of stool.

This revised, collapsed network was run, with separate nodes for frequency of STH deworming to further explore the importance of frequency in a network with eight nodes. The Advisory Group recommended combining all helminth deworming drugs into one node for high frequency dosage, and a second node for regular frequency dosage. The rationale for keeping frequency separate was that more frequent deworming could provide more constant levels of lower worm burden.

At the November 2017 meeting of investigators and the Advisory Group, the results for high versus regular frequency of STH deworming were presented and considered not different (e.g weight gain for STH deworming at high frequency was −0.01 kg, 95% CI: −0.13, 0.10) and for regular frequency weight gain was 0.13 kg (95% CI: 0.04, 0.22) hence the network was further reduced to six nodes (Figure 13). Since the results may be influenced by these decisions about collapsing across nodes, the Advisory Board and research team decided to also analyse the full network as a sensitivity analysis.

5.9.1 Assessing feasibility of NMA with IPD

Assumptions of transitivity and consistency

Transitivity was considered plausible because we assessed the distribution of child-level effect modifiers across studies, and found...
| Studies                | Maternal education                      | Socioeconomic status                                                                 | Cognition                                                                                     |
|------------------------|-----------------------------------------|---------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| Beasley (1999)         | NA                                      | House made of concrete (yes, no) Owns home (yes, no) Owns a sewing machine (yes, no) Owns a radio (yes, no) | NA                                                                                             |
| Beasley (1995)         | NA                                      | House made of concrete (yes, no) Flushing toilet (yes, no) Owns home (yes, no) Owns a sewing machine (yes, no) Owns a bike (yes, no) Owns a radio (yes, no) | NA                                                                                             |
| Liu et al. (2017)      | Mother has attended secondary school (yes, no) | Individual level Boarding at school Ethnicity Household level Number of siblings Number of pieces of durable assets Parents who are working migrants (yes, no) Mother has attended secondary school (yes, no) Father has attended secondary school (yes, no) Dirt floor (yes, no) Dirt-based latrines (yes, no) | Working memory index (digit span, letter numbering sequencing) Processing speed index (coding, symbol search) |
| Ebenezer (2013)        | Total number of years in school Poor (yes, no) Father’s total number of years in school | Math scores Tamil scores Single digit attention scores Double digit attention scores |                                                                                               |
| Ndibazza et al. (2012) | Level of education (none, primary, secondary, tertiary) Household SES scored (1–6) based on building materials of the home, number of rooms, and items owned | General cognitive abilities (block design, picture vocabulary scale) Cognitive flexibility (Wisconsin card sort test) Measure of attention (picture search) Working memory (sentence repetition, verbal fluency, counting span, running memory) Motor abilities (coin box, balancing on one leg) Measure of planning (Tower of London) Measures of inhibition (tap once tap twice; shapes task) |                                                                                               |
| Nga (2009)             | Level of education (illiterate, primary, secondary, high school, college) Percentage of households classified as “poor” | Raven’s coloured progressive matrices test Working memory (digit span forward, digit span backward) Processing speed index (coding, block design) Math scores Vietnamese language scores |                                                                                               |
| Rohner                 | NA                                      | NA                                                                                    | Raven score Coding total Symbols total Target marking errors Target marking time                    |
| Solon (2003)           | NA                                      | NA                                                                                    | Verbal ability Quantitative ability Nonverbal ability Total cognition                                                                                     |
similar distributions across studies for all covariates (Figures 2–13). In addition, we found that the distribution of effect modifiers was balanced across comparisons (Table S17). As shown by the evidence network, the treatments are given for the same indication and compared in the same studies, with numerous connected nodes in the full network (with 18 nodes) as well as the collapsed evidence network (six nodes; Table 9).

Methodological and clinical heterogeneity was considered appropriate for pooling by considering the settings, population characteristics and interventions. Statistical heterogeneity within each treatment comparison was tested by constructing forest plots for each direct comparison. Heterogeneity as measured by the $I^2$ statistic was <75% for all direct comparisons (Appendix 3, Forest plots).

### 5.10 | Funnel plot

As above, the only comparison with >10 studies providing IPD was STH deworming versus placebo, with nine studies with sufficient data for multiple imputation of missing data, and four studies with >50% missing data (Kirwan et al., 2009; Miguel & Kremer, 2004; Rousham & Mascie-Taylor, 1994; Wiria et al., 2013).

As planned, we constructed a funnel plot to assess the presence of publication bias. To do this, we included all studies of STH versus placebo from our previous Campbell review of deworming (Welch et al., 2016) to compare the received data with the data which was either not received or ineligible (due to lack of baseline infection intensity data).

The funnel plot of STH deworming versus placebo for the studies for which we received data (circles) shows that the studies we received include both positive and negative studies (Figure 14). The studies which were not received had larger effects on weight gain and were smaller (diamonds).

The Egger test for publication bias on the aggregate data of the entire sample ($n = 30$ studies) was not statistically significant ($p = .249$) for small study effects.

### 5.11 | Main effects

This section provides the overall results on our four primary outcomes: weight, height, haemoglobin and cognition, using the collapsed evidence

---

**TABLE 8** (Continued)

| Studies       | Maternal education   | Socioeconomic status                      | Cognition                              |
|---------------|----------------------|-------------------------------------------|----------------------------------------|
| Stoltzfus (2004) | NA                   | NA                                        | Language development (18 items)        |
|               |                      |                                           | Motor development (20 items)           |
| Yap (2014)    | Parents’ level of education | Parents’ level of education (literate, primary, secondary, above) | NA                                     |
|               | (literate, primary, secondary, above) | Household income source (agriculture, teacher/government official, own business, worker) | |

Abbreviation: SES, socioeconomic status.
network, which we decided was the most clinically sensible and policy-relevant. The results are based on studies with a median duration of 7 months (ranging from 4 to 45 months).

These findings are summarised in three summary of findings tables. Following this section, we describe effect modifier analyses for each planned effect modifier for each outcome of interest. A road map of all analyses is described in Table S10. Results for main effects of NMA with IPD for the base case are in Table S11.

5.11.1 | Weight

Base case IPD-NMA analysis
There were no statistically significant effects on weight gain (kg) for any of the deworming combinations compared to placebo. For STH deworming versus placebo, the effect on weight gain was 0.01 kg (95% CI: −0.08, 0.11; Figure 15).

The head-to-head comparisons of deworming treatment combinations produced results that were consistent in direction and size with the results of the treatment versus placebo comparisons.

Direct evidence-aggregate and IPD
For each comparison, we compared the IPD-NMA result with the results for the direct evidence from study results pooled at the aggregate level (adjusted for covariates) and the direct evidence pooled using IPD (adjusted for covariates).

In all cases, the effect estimates from direct evidence were of similar size and direction as the IPD-NMA indirect + direct effect estimates (Table 10), and the heterogeneity of direct comparisons was below an I² of 75% (Table 11). The forest plot for one comparison (deworming for STH vs. placebo) is shown in Figure 16.

The effect estimates for all other comparisons are shown in Appendix 3 with details for each study for each comparison (Appendix 3).

Sensitivity analyses
There were no qualitative (different directions of effects) nor quantitative (different sizes of effects) differences in the analyses conducted with no covariates (unadjusted analyses; Table S12). For example, the unadjusted effect on weight gain was 0.01 (−0.08, 0.11) for STH versus placebo.

The results of a complete case analysis with the same 14 studies from the base case, where missing data were not imputed, was congruent with the main effects described above (Table S12). For example, the effect on weight gain for STH deworming versus placebo was 0.03 kg (95% CI: −0.07, 0.13).

The complete case analysis with an additional five studies (Hall et al., 2006; Kirwan et al., 2009; Miguel & Kremer, 2004; Rousham & Mascie-Taylor, 1994; Wiria et al., 2013) which had too much missing data (>50%) for multiple imputation was congruent with our base case analysis. For example, the effect on weight gain for STH deworming versus placebo was 0.01 kg (95% CI: −0.11, 0.12).

Analysis of the NMA model restricted to studies at low risk of bias yielded similar results (Table S12) for weight gain (kg) for STH versus placebo (0.01 kg, 95% CI: −0.10, 0.12). However, there were...
**TABLE 9** Comparison of node constitution in full network, June 2017 collapsed network and November 2017 network model

| Full network | Collapsed network1 (8 nodes)Jun 2017 Advisory Group meeting | Collapsed network2 (6 nodes)November 2017 Advisory Group meeting |
|--------------|-------------------------------------------------------------|---------------------------------------------------------------|
| 1 Placebo or control | Placebo or control | Placebo or control |
| 2 Albendazole | STH deworming with any drug at regular frequency | STH deworming with any drug |
| 3 Praziquantel | STH deworming with any drug at high frequency | Any STH deworming combination with praziquantel |
| 4 Albendazole with praziquantel | Any STH deworming combination at regular frequency with praziquantel with or without iron or micronutrients | Any STH deworming combination with praziquantel with or without iron or micronutrients |
| 5 Albendazole (high) with praziquantel with iron | Any STH deworming combination at high frequency with praziquantel with or without iron or micronutrients | Any STH deworming combination with praziquantel with iron or micronutrients |
| 6 Albendazole (high) with praziquantel | Any STH deworming at regular frequency with praziquantel with or without iron or micronutrients | Micronutrients or iron alone |
| 7 Iron fortified (food/beverage) | Any STH deworming at high frequency with praziquantel with or without iron or micronutrients | Micronutrients or iron alone |
| 8 Iron supplement (tablet/liquid) | Micronutrients or iron alone | |
| 9 Mebendazole (high) | | |
| 10 Micronutrient tablet | | |
| 11 Albendazole with praziquantel with micronutrient tablet | | |
| 12 Albendazole with micronutrient fortified (food/beverage) | | |
| 13 Mebendazole (high) with iron fortified (food/beverage) | | |
| 14 Mebendazole with iron tablet | | |
| 15 Micronutrient fortified (food/beverage) | | |
| 16 Mebendazole (regular) | | |
| 17 Mebendazole (high) with iron supplement (tablet/liquid) | | |
| 18 Albendazole (regular) with praziquantel with iron | | |

Abbreviation: STH, soil-transmitted helminthiasis.

**FIGURE 14** Funnel plot for weight gain (kg) for all studies of STH deworming versus placebo. STH, soil-transmitted helminthiasis
larger effects for praziquantel with or without STH deworming versus placebo (0.17 kg, 95% CI: −0.28, 0.62) compared to 0.04 kg (−0.11 to 0.19) in base case) or praziquantel with STH deworming and micronutrients or iron (0.34 kg, 95% CI: −0.10, 0.78) compared to −0.03 kg, 95% CI: −0.27, 0.21). These latter comparisons also had wider CIs due to smaller numbers of participants.

We assessed the full evidence network with 18 nodes with our 14 base case studies, with multiple imputation for missing data and adjusted for covariates as a sensitivity analysis to allow comparison of separate drugs such as albendazole and mebendazole at different frequencies to our main model findings with the collapsed network. These analyses had wider CIs (Table S12). In this analysis, we found some larger effects on weight gain than in the collapsed model. For example, the effect of mebendazole twice per year versus placebo was 0.25 kg (95% CI: −0.37, 0.86). For praziquantel alone versus placebo, the effect was 0.18 kg (95% CI: −0.19, 0.56) compared to 0.04 kg (−0.11, 0.19) in the base case. None of these effects were statistically significant.

One study had very precise results and received a lot of weight in the meta-analyses for weight and height gain (Nga et al., 2009). We conducted a sensitivity analysis without this study and found the same effect on weight gain for STH versus placebo (0.01 kg, 95% CI: −0.08, 0.11). Other effect sizes were also of a similar magnitude and direction as the base case.

As described above, there was variation in effect of deworming on infection prevalence at endline (Beasley et al., 1999; Friis et al., 2003; Le Huong et al., 2007; Nga et al., 2009; Stoltzfus et al., 1997, 2004). The results of this sensitivity analysis show that for STH deworming versus placebo, the effect on weight gain was 0.08 kg, 95% CI (−0.10, 0.26), whereas our basecase analysis findings were 0.10 kg (95% CI: −0.08, 0.11).

**Comparison of effect sizes for weight gain (kg) between received data and studies that were not included in the analysis**

We assessed whether the effects on weight gain were similar for these studies which did not provide data (either because they did not provide it or because they did not meet eligibility criteria) to the studies which did provide data (Appendix 3). For the STH versus placebo comparison, using aggregate data, the effect size for the studies for which we received data was 0.02 kg (95% CI: −0.04, 0.08) (13 studies, I² 12%) compared to an effect size for the studies we did not receive of 0.13 kg (95% CI: 0.01, 0.25) (n = 15 studies, I² 71%).

**TABLE 10** Comparison of direct and indirect evidence for weight gain (kg) for STH versus placebo

| Analysis                      | Effect estimate of STH vs. placebo, weight gain (kg) | I²  |
|-------------------------------|-------------------------------------------------------|-----|
| Aggregate-direct adjusted     | 0.05 (−0.02, 0.11)                                     | 11% |
| IPD-direct adjusted           | 0.013 (−0.088, 0.115)                                  |     |
| IPD-NMA-Direct + indirect     | 0.01 (−0.08, 0.11)                                     |     |

**TABLE 10** Comparison of direct and indirect evidence for weight gain (kg) for STH versus placebo

| Analysis                      | Effect estimate of STH vs. placebo, weight gain (kg) |
|-------------------------------|-------------------------------------------------------|
| Aggregate-direct adjusted     | 0.05 (−0.02, 0.11)                                     |
| IPD-direct adjusted           | 0.013 (−0.088, 0.115)                                  |
| IPD-NMA-Direct + indirect     | 0.01 (−0.08, 0.11)                                     |

Abbreviation: IPD, individual participant data; STH, soil-transmitted helminthiasis.
The interaction test for subgroup differences was not statistically significant ($p = .10$). The pooled effect of all 28 studies was 0.07 kg, 95% CI (0.00, 0.13).

The above analysis only includes studies which randomised STH alone compared to a placebo or control arm. Studies with vitamin A, iron or praziquantel as cointerventions are not included in this analysis since we decided that STH deworming and cointerventions should be considered as separate nodes. The latter analysis omits one study (Stephenson et al., 1989) which was also omitted from our previous meta-analysis (Welch et al. 2016). In our previous systematic review, we identified baseline imbalance in the Stephenson 1989 study for hookworm prevalence (95% vs. 79%) and infection intensity (1,183 epg vs. 394 epg for the control group). This baseline imbalance is larger than expected by chance and may have biased the study to find larger effects since sicker children were in the intervention group. The effect was 1.3 kg greater weight gain with a single dose of albendazole (400 mg) compared to placebo after 6 months. When included in our analysis, the $I^2$ was 89%, suggesting pooling is inappropriate. There may have been other factors related to this study which led to a larger weight gain than seen in any of the other 28 studies of STH deworming versus placebo. The Stephenson et al. (1993) study conducted in the same area in Kenya found an effect of 1.1 kg on weight gain of a single dose of Albendazole over 8.2 months.

### 5.11.2 Height

#### Height-base case analysis

The effect on height gain for STH deworming versus placebo was 0.09 cm (95% CI: −0.08, 0.27). The effects for the other comparisons were of similar magnitude (Figure 17).

### Comparison of effect sizes for height gain (cm) between received data and studies that did not provide data

We assessed whether the effects on height gain were similar for these studies which did not provide data (either because they did not provide it or because they did not meet eligibility criteria) to the studies which did provide data (Appendix 3). The test for interaction

**TABLE 11** Heterogeneity of direct evidence comparisons

| Comparisons                        | Effect estimate and heterogeneity of direct evidence (pooled at aggregate level) |
|------------------------------------|---------------------------------------------------------------------------------|
| STH deworming vs. placebo          | 0.05 (−0.02, 0.11), $I^2 = 11\%$, 9 studies                                    |
| PZQ alone or with STH vs. placebo  | 0.04 (−0.12, 0.20), $I^2 = 0\%$, 5 studies                                     |
| PZQ with MCN/iron vs. placebo      | 0.13 (−0.28, 0.54), $I^2 = 67\%$, 3 studies                                   |
| STH deworming with MCN/iron vs. placebo | 0.00 (−0.07, 0.08), $I^2 = 0\%$, 5 studies                                    |
| MCN/iron vs. placebo               | 0.01 (−0.07, 0.09), $I^2 = 6\%$, 6 studies                                    |

Abbreviations: MCN, micronutrients; PZQ, praziquantel; STH, soil-transmitted helminthiasis.

The head-to-head comparisons of STH deworming treatment combinations produced results that were consistent in expected direction and size with the results of the treatment versus placebo comparisons.

**Direct evidence-aggregate and IPD**

Comparison of the analyses of height gain for STH versus placebo for aggregate data, IPD direct estimates and IPD-NMA estimates are congruent in size and direction of effect (Table 12).

The forest plots for each direct evidence comparison were of acceptable heterogeneity to carry out NMA (Table 13).

**Sensitivity analyses**

There were no qualitative (different directions of effects) nor quantitative (different sizes of effects) differences in any of the sensitivity analyses including: (a) unadjusted analyses, (b) complete case (unadjusted), (c) studies at low risk of bias, (d) full model with 18 nodes and (e) complete case with additional five studies that had too much missing data to be included in the adjusted models (Tables S12 and S13).

As an example, the effect sizes for the STH versus placebo comparison for height gain are in the table below (Table 14).
for subgroup difference was not statistically significant ($p = .25$), with an effect on height gain for studies for which we received data of 0.04 cm (95% CI: −0.04, 0.12) compared to an effect of 0.24 cm (95% CI: −0.01, 0.30). The pooled effect on height gain across these 28 studies for STH deworming versus placebo was 0.09 cm (95% CI: 0.01, 0.17). This analysis included four studies of SAT (Sarkar, Anwar, Biswas, & Mannan, 2002; Simeon et al., 1995; Tee, Lee, Noorizan, Noori, & Raj, 2013; Yap et al., 2014) since we decided to include these studies since our model adjusts for infection intensity. In this aggregate level analysis, there is no adjustment for infection intensity.

### 5.11.3 | Haemoglobin

**Haemoglobin base case analyses**

The effect of STH deworming alone versus placebo was 0.32 g/L (95% CI: −0.63, 1.26) (Figure 18). Deworming for schistosomiasis with or without STH deworming increased haemoglobin by 1.85 g/L (95% CI: 0.53, 3.18) versus placebo. Deworming for schistosomiasis with or without STH deworming and micronutrients or iron increased haemoglobin by 2.72 g/L (95% CI: 1.05, 4.40) compared to placebo. Deworming for STH combined with iron and/or micronutrients increased haemoglobin by 1.98 g/L (95% CI: 0.74, 3.21) compared to placebo. The effect of micronutrients and/or iron versus placebo was 1.28 g/L (95% CI: 0.07, 2.49). This latter effect must be interpreted with caution since there are many other studies of micronutrient and iron supplementation in children that are not included in this review.

**TABLE 12** Comparison of direct and indirect estimates for STH versus placebo for height gain

| Analysis                  | Effect estimate of STH vs. placebo, height (cm) | $I^2$ |
|---------------------------|--------------------------------------------------|------|
| Aggregate-direct adjusted | 0.04 (−0.04, 0.11)                               | 11% |
| IPD-direct adjusted       | 0.010 (−0.10, 0.30)                              |     |
| IPD-NMA-direct + indirect evidence (adjusted) | 0.09 (−0.08, 0.27) |      |

Abbreviation: IPD, individual participant data; NMA, network meta-analysis; STH, soil-transmitted helminthiasis.

**Direct evidence aggregate and IPD**

When comparing the three effect sizes of aggregate direct evidence, IPD direct evidence and IPD-NMA direct and indirect evidence, we show the results below for the STH versus placebo and STH + micronutrients/iron comparisons to placebo, showing similar size and direction of effects for both comparisons (Table 15).

Analysis of the direct evidence of aggregate data from studies confirmed heterogeneity <75% for all comparisons (Appendix 3).

**Sensitivity analyses**

All sensitivity analyses were congruent with these main findings including the complete case model (14 studies, six nodes, unadjusted), complete case with additional five studies (unadjusted) and the unadjusted 14 study model (Table 16).

Analysis of the six studies with greatest impact on *A. lumbricoides* prevalence at endline (relative risk of 0.80 or greater when compared
found an effect of 2.74 g/L (95% CI: 0.95, 4.52) of STH deworming with micronutrients or iron compared to placebo.

**Comparison of effect sizes for haemoglobin (g/L) between received data and studies that did not provide data**

We assessed whether the effects on haemoglobin were similar for these studies which did not provide data (either because they did not provide it or because they did not meet eligibility criteria) to the studies which did provide data (Appendix 3). The test for interaction for subgroup differences for STH deworming versus placebo was not statistically significant ($p = .33$). The effect size was 0.05 g/L (95% CI: $-0.02, 0.11$) compared to an effect size of studies for which data was not received of 0.00 (95% CI: $-0.05, 0.06$). Also, when sorted by year of publication, there was no pattern in effect size based on the year in which the study was published.

### 5.11.4 Cognition

Six studies provided IPD data on cognition outcomes (Ebenezer et al., 2013; Liu et al., 2017; Nga et al., 2009; Rohner et al., 2010; Solon et al., 2003; Stoltzfus et al., 2004). These were analysed separately for each study.

The baseline means and range of minimum and maximum scores at baseline are given below to aid in interpreting the effect sizes observed (Table 17).

Nga et al. (2009) found that digit forward was 0.38 (95% CI: 0.06, 0.71) units higher for albendazole + fortified biscuit compared to unfortified biscuit, and that digit forward was also improved for fortified biscuit alone compared to unfortified biscuit (0.57, 95% CI: 0.25, 0.88). All other outcomes had nonsignificant effects (see Table 18).

### 5.12 Effect modifier analyses

We conducted subgroup analyses across each of the nine factors that were deemed important by our advisory group.

There were insufficient numbers of children with moderate and high intensity infections (as defined using the WHO cut-offs) to run the NMA model. Thus, we decided with our advisory board to use three categories based on the distribution to assess whether there is a gradient in effect across infection intensity. Light and moderate infection intensity cutoffs were defined by the median infection intensity in children who were infected across the whole population of children in all 14 studies in the base case.

To further assess whether there was a gradient in effect size across infection intensity, we conducted subgroup analysis for the comparison with the most available data (STH deworming vs. placebo). In this comparison of direct evidence from trials, 15% of children had moderate or heavy infections according to WHO cut-offs for ascaris, $T. trichiura$ and hookworm.

#### 5.12.1 BMI for age as effect modifier

**Weight**

Tests for interaction across BMI for age were not statistically significant for weight gain across any comparison (Figures S13 and Table S18).

**Height**

Tests for interaction were not statistically significant across BMI for age for height gain in cm for any comparison (Figure S14; Tables S15 and S18).

**Haemoglobin**

There were no statistically significant subgroup differences across BMI for age for change in haemoglobin for any comparison (Figure S15 and Table S15).

**Cognition**

The test for interaction was not statistically significant across BMI for age for cognition for any comparison (Table S16).
5.12.2  |  Height for age-as effect modifier

Weight
The test for interaction was not statistically significant across levels of height for age for weight gain for any comparison (Figure S16 and Table S18).

Height
The test for interaction was not statistically significant across levels of height for age for height gain for any comparison (Figure S17 and Table S18).

Haemoglobin
The test for interaction was not statistically significant across levels of height for age for change in haemoglobin for any comparison (Figure S18 and Table S18).

| TABLE 15  | Direct and indirect evidence for haemoglobin STH versus placebo |
|-----------|---------------------------------------------------------------|
| Analysis  | Effect size STH vs. placebo | STH+MCN/iron vs. placebo |
| Direct-aggregate | 0.23 (−0.52, 0.97) | 2.18 (1.02, 3.35), I² 0% |
| Direct IPD | 0.22 (−0.74,1.19) | 1.76 (0.41,3.11) |
| IPD-NMA direct and indirect | 0.32 (−0.63,1.26) | 1.98 (0.74,3.21) |

Abbreviation: IPD, individual participant data; MCN, micronutrients; NMA, network meta-analysis; STH, soil-transmitted helminthiasis.

5.12.3  |  Sex, as an effect modifier

Weight
The test for interaction for subgroup effects was not statistically significant across sex for weight gain for any comparison (Figure S19 and Table S16).

Height
The test for interaction for subgroup effects was not statistically significant across sex for height gain for any comparison (Figure S20 and Table S16).

Cognition
When cognition for each of six studies (Ebenezer, Liu, Nga, Rohner, Solon and Stoltzfus 2004) was analysed according to subgroups of height for age of stunted (<−2 HAZ) or not stunted (≥−2.0 HAZ), there were no statistically significant effects on cognition, except for three comparisons. In these comparisons, albendazole combined with fortified biscuits resulted in better improvement of −0.85 units on digit forward (95% CI: −1.52, −0.18) compared to −0.20 (95% CI: −0.57, 0.17) for children who were not stunteda. In the same study (Nga), fortified biscuits resulted in improvement of digit forward of −0.54 (9% CI: −0.90 to −0.18) for children with normal HAZ (≥−2), and similar improvement in stunted children (−0.78 digit forward units, 95% CI: −1.42, −0.14) (Table S16).
Haemoglobin

The test for interaction for subgroup effects was not statistically significant across sex for change in haemoglobin for any comparison (Figure S21 and Table S16).

Cognition

Tests for interaction for subgroup effects across sex were not statistically significant for cognition for any outcome measure or any comparison (Table S16).

5.12.4 | Age, as effect modifier

Weight

Tests for interaction for subgroup effects across age were not statistically significant for weight gain for any comparison (Figure S22 and Table S16).

Height

The relatively small number of participants <5 years of age led to wide CIs for estimates in this age group. Tests for interaction for subgroup effects across age were not statistically significant for height gain for any comparison (Figure S23 and Table S16).

Haemoglobin

Some comparisons did not have any children <5 years of age. Tests for interaction for subgroup effects across age were not statistically significant for change in haemoglobin for any comparison (Figure S24).

Cognition

Studies that reported cognition outcomes did not have children <5 years.

5.12.5 | A. lumbricoides, as effect modifier

We conducted two analyses because of the limited number of children with moderate or heavy intensity infections:

1) NMA with IPD using cutoffs based on the distribution of intensity in the sample of three levels, and

2) Direct evidence analysis with IPD using WHO cutoffs for intensity of infection.

Weight

For the NMA-IPD, tests for interaction for subgroup effects across A. lumbricoides intensity were not statistically significant for weight gain for the NMA. When using cut-offs for intensity of infection for A. lumbricoides based on the median distribution across three levels:

| Studies | Outcome | Mean | Minimum | Maximum |
|---------|---------|------|---------|---------|
| Stoltzfus04 | Language skills | 10.2 | 0.0 | 18.0 |
| | Motor skills | 13.7 | 0.0 | 20.0 |
| Solon | Verbal ability | 7.5 | 0.0 | 16.0 |
| | Quantitative ability | 7.4 | 0.0 | 12.0 |
| | Nonverbal ability | 2.7 | 0.0 | 7.0 |
| | Total cognition | 17.6 | 2.0 | 34.0 |
| Rohner | Raven score | 13.3 | 1.0 | 22.0 |
| | Coding total | 18.0 | 3.0 | 43.0 |
| | Symbols total | 8.6 | 1.0 | 20.0 |
| | Target marking errors | 0.1 | 0.0 | 8.0 |
| | Target marking time | 45.5 | 20.0 | 105.0 |

### Table 16: Sensitivity analyses for haemoglobin

| Sensitivity analysis | STH vs. placebo | STH+MCN/iron vs. placebo |
|---------------------|-----------------|---------------------------|
| Base case           | 0.32 (−0.63, 1.26) | 1.98 (0.74, 3.21) |
| Unadjusted analyses | 0.32 (−0.63, 1.26) | 1.98 (0.74, 3.21) |
| Complete case (unadjusted), 14 studies | 0.30 (−0.69, 1.29) | 3.18 (1.28, 5.09) |
| Studies at low risk of bias | 0.07 (−1.05, 1.19) | 2.48 (0.57, 4.39) |
| Full model with 18 nodes, 14 studies | Albenzazole 2/year: 0.16 (−0.86, 1.17) | Alben 2/year + fortified beverage: 0.69 (−1.09, 2.48) |
| | Mebendazole 2/year: −0.10 (−6.61, 6.41) | Meben 2/year + iron: 2.73 (−0.06, 5.51) |
| Complete case with additional five studies | 0.37 (−0.77, 1.51) | 1.83 (0.05, 3.61) |
| Studies with greater impact on infection prevalence | 0.72 (−1.06, 2.50) | 2.74 (0.95, 4.52) |

Abbreviation: MCN, micronutrients; STH, soil-transmitted helminthiasis.

### Table 17: Baseline cognition measures for each study

| Studies | Outcome | Mean | Minimum | Maximum |
|---------|---------|------|---------|---------|
| Ebenezer | Single digit attention score | 12.2 | 0.0 | 20.0 |
| | Double digit attention score | 7.2 | 0.0 | 20.0 |
| | Math score | 34.4 | 0.0 | 100.0 |
| | Tamil language score | 43.2 | 0.0 | 100.0 |
| Liu | Processing speed index | 86.2 | 45.0 | 138.0 |
| | Working memory index | 78.6 | 45.0 | 147.0 |
| | TIMSS z score | 0.0 | −2.4 | 2.1 |
| Nga | Raven score | 16.4 | 0.0 | 35.0 |
| | Digit forward | 7.0 | 2.0 | 9.0 |
| | Digit back | 2.9 | 0.0 | 8.0 |
| | Block score | 11.9 | 0.0 | 47.0 |
| | Code score | 31.3 | 1.0 | 55.0 |
| Stoltzfus04 | Language skills | 10.2 | 0.0 | 18.0 |
| | Motor skills | 13.7 | 0.0 | 20.0 |
| Solon | Verbal ability | 7.5 | 0.0 | 16.0 |
| | Quantitative ability | 7.4 | 0.0 | 12.0 |
| | Nonverbal ability | 2.7 | 0.0 | 7.0 |
| | Total cognition | 17.6 | 2.0 | 34.0 |
| Rohner | Raven score | 13.3 | 1.0 | 22.0 |
| | Coding total | 18.0 | 3.0 | 43.0 |
| | Symbols total | 8.6 | 1.0 | 20.0 |
| | Target marking errors | 0.1 | 0.0 | 8.0 |
| | Target marking time | 45.5 | 20.0 | 105.0 |
| Study   | Cognition outcome                  | Comparator | Treatment                        | EE (no covariates) | 95% LCI | 95% UCI |
|---------|-----------------------------------|------------|----------------------------------|--------------------|---------|---------|
|         |                                   |            |                                  | EE (IPD-NMA covariates) | 95% LCI | 95% UCI |
|         |                                   |            |                                  | EE Diff. (NMA cov. − No cov.) | 95% LCI | 95% UCI |
|         |                                   |            |                                  |                     |         |         |
| EBenezer| Short-term attention               | Placebo    | Mebendazole + iron               | -1.11              | -1.09   | 0.87    |
|         |                                   | Placebo    | Placebo                          | -0.11              | -0.07   | 0.02    |
|         |                                   | Placebo    | Placebo                          | -1.08              | -0.07   | 0.02    |
|         |                                   | Placebo    | Placebo                          | -0.11              | -0.07   | 0.02    |
| Liu     | Processing speed                   | Placebo    | Albendazole                      | 0.84               | 0.39    | 2.07    |
|         |                                   | Placebo    | Placebo                          | 0.45               | 0.05    | 1.42    |
|         |                                   | Placebo    | Placebo                          | 0.13               | 0.04    | 0.41    |
|         |                                   | Placebo    | Placebo                          | 0.13               | 0.04    | 0.41    |
|         |                                   | Placebo    | Placebo                          | 0.13               | 0.04    | 0.41    |
| Nga     | Digit forward                      | Placebo    | Albendazole                      | 0.26               | 0.38    | 0.39    |
|         |                                   | Placebo    | Placebo                          | 0.03               | 0.00    | 0.00    |
|         |                                   | Placebo    | Placebo                          | 0.03               | 0.00    | 0.00    |
|         |                                   | Placebo    | Placebo                          | 0.03               | 0.00    | 0.00    |
| Nga     | Digit back                         | Placebo    | Albendazole                      | 0.26               | 0.07    | 0.22    |
|         |                                   | Placebo    | Placebo                          | 0.04               | -0.06   | 0.08    |
|         |                                   | Placebo    | Placebo                          | 0.04               | -0.06   | 0.08    |
|         |                                   | Placebo    | Placebo                          | 0.04               | -0.06   | 0.08    |
| Nga     | Digit back                         | Placebo    | Albendazole + micronutrients     | 0.26               | 0.25    | 0.28    |
|         |                                   | Placebo    | Placebo                          | 0.07               | 0.09    | 0.097   |
|         |                                   | Placebo    | Placebo                          | 0.07               | 0.09    | 0.097   |
|         |                                   | Placebo    | Placebo                          | 0.07               | 0.09    | 0.097   |
| Nga     | Target marking time                | Placebo    | Albendazole + praziquantel + iron| 0.26               | 0.24    | 0.27    |
|         |                                   | Placebo    | Placebo                          | 0.11               | 0.06    | 0.17    |
|         |                                   | Placebo    | Placebo                          | 0.11               | 0.06    | 0.17    |
|         |                                   | Placebo    | Placebo                          | 0.11               | 0.06    | 0.17    |
| Nga     | Target marking time                | Placebo    | Albendazole + praziquantel + iron| 0.26               | 0.24    | 0.27    |
|         |                                   | Placebo    | Placebo                          | 0.11               | 0.06    | 0.17    |
|         |                                   | Placebo    | Placebo                          | 0.11               | 0.06    | 0.17    |
| Nga     | Target marking time                | Placebo    | Albendazole + praziquantel + iron| 0.26               | 0.24    | 0.27    |
|         |                                   | Placebo    | Placebo                          | 0.11               | 0.06    | 0.17    |
|         |                                   | Placebo    | Placebo                          | 0.11               | 0.06    | 0.17    |

(Continues)
| Study       | Treatment                          | Comparator | Cognition outcome | EE (no covariates) | 95% LCI  | 95% UCI | EE (IPD-NMA covariates) | 95% LCI  | 95% UCI | EE Diff. (NMA cov. – No cov.) |
|-------------|------------------------------------|------------|-------------------|--------------------|----------|---------|--------------------------|----------|---------|-------------------------------|
| Ebenezer    | Mebendazole + iron                 | Placebo    | Math score        | 2.30               | -0.24    | 4.84    | 2.31                     | -0.19    | 4.81    | -0.01                         |
| Ebenezer    | Mebendazole + iron                 | Placebo    | Tamil language    | -1.37              | -3.79    | 1.06    | -1.34                    | -3.73    | 1.06    | -0.03                         |
| Liu         | Albendazole                        | Placebo    | TIMSS z score     | -0.03              | -0.11    | 0.05    | -0.03                    | -0.11    | 0.05    | 0.00                          |
| Nga         | Albendazole                        | Placebo    | Block score       | 1.14               | -0.59    | 2.88    | 1.03                     | -0.71    | 2.77    | 0.11                          |
| Nga         | Albendazole                        | Placebo    | Code score        | -0.01              | -2.20    | 2.18    | 0.14                     | -2.05    | 2.32    | -0.15                         |
| Nga         | Albendazole + micronutrients       | Placebo    | Block score       | -0.71              | -2.52    | 1.10    | -0.63                    | -2.45    | 1.19    | -0.08                         |
| Nga         | Albendazole + micronutrients       | Placebo    | Code score        | 1.19               | -0.98    | 3.35    | 1.21                     | -0.95    | 3.37    | -0.02                         |
| Nga         | Micronutrients                     | Placebo    | Block score       | -0.53              | -2.28    | 1.21    | -0.58                    | -2.34    | 1.18    | 0.05                          |
| Nga         | Micronutrients                     | Placebo    | Code score        | 1.28               | -0.94    | 3.51    | 1.38                     | -0.84    | 3.61    | -0.10                         |
| Solon       | Albendazole                        | Placebo    | Verbal ability    | -0.01              | -0.61    | 0.60    | -0.02                    | -0.63    | 0.58    | 0.01                          |
| Solon       | Albendazole                        | Placebo    | Quantitative ability | 0.04             | -0.41    | 0.48    | 0.01                     | -0.44    | 0.45    | 0.03                          |
| Solon       | Albendazole + micronutrients       | Placebo    | Verbal ability    | 0.38               | -0.18    | 0.94    | 0.38                     | -0.18    | 0.94    | 0.00                          |
| Solon       | Albendazole + micronutrients       | Placebo    | Quantitative ability | 0.06            | -0.37    | 0.49    | 0.05                     | -0.38    | 0.48    | 0.01                          |
| Solon       | Albendazole + micronutrients       | Placebo    | Nonverbal ability | -0.10              | -0.47    | 0.27    | -0.08                    | -0.46    | 0.29    | -0.02                         |
| Solon       | Micronutrients                     | Placebo    | Verbal ability    | 0.15               | -0.39    | 0.70    | 0.11                     | -0.44    | 0.66    | 0.04                          |
| Solon       | Micronutrients                     | Placebo    | Quantitative ability | 0.17            | -0.27    | 0.61    | 0.16                     | -0.28    | 0.60    | 0.01                          |
| Solon       | Micronutrients                     | Placebo    | Nonverbal ability | -0.11              | -0.51    | 0.29    | -0.08                    | -0.48    | 0.31    | -0.03                         |
| Development | Nga                                 | Albendazole | Raven score       | 0.05               | -1.04    | 1.14    | 0.00                     | -1.06    | 1.07    | 0.05                          |
| Nga         | Albendazole + micronutrients       | Placebo    | Raven score       | 0.19               | -0.93    | 1.31    | 0.14                     | -0.96    | 1.24    | 0.06                          |
| Nga         | Micronutrients                     | Placebo    | Raven score       | 0.82               | -0.26    | 1.90    | 0.80                     | -0.26    | 1.86    | 0.02                          |
| Rohner      | Albendazole + praziquantel         | Placebo    | Raven score       | 0.89               | NA       | NA      | 0.98                     | -1.07    | 3.02    | -0.08                         |
| Rohner      | Albendazole + praziquantel + iron  | Placebo    | Raven score       | -1.04              | NA       | NA      | -1.24                    | -3.23    | 0.75    | 0.20                          |
| Rohner      | Iron fortified food or beverage    | Placebo    | Raven score       | -1.44              | NA       | NA      | -1.40                    | -3.47    | 0.67    | -0.04                         |
| Stoltzfus04 | Iron                               | Placebo    | Language skills   | 0.17               | -1.03    | 1.38    | 0.41                     | -0.77    | 1.59    | -0.24                         |
| Stoltzfus04 | Iron                               | Placebo    | Motor development | 0.01               | -0.08    | 0.09    | -0.01                    | -0.09    | 0.07    | 0.02                          |
| Stoltzfus04 | Mebendazole (high)                 | Placebo    | Language skills   | 0.06               | -1.13    | 1.25    | 0.31                     | -0.87    | 1.50    | -0.26                         |
| Stoltzfus04 | Mebendazole (high)                 | Placebo    | Motor development | 0.02               | -0.06    | 0.11    | 0.00                     | -0.09    | 0.09    | 0.02                          |
| Stoltzfus04 | Mebendazole (high) + iron          | Placebo    | Language skills   | 0.36               | -0.77    | 1.49    | 0.60                     | -0.52    | 1.73    | -0.24                         |
none detected, lighter intensity (1–1,776 epg), and higher intensity (>1,776 epg), the effect for children with higher intensity was 0.08 kg (95% CI: −0.13, 0.29) (Table S15).

For the analysis of STH deworming versus placebo using direct evidence only for weight across three levels of *A. lumbricoides* infection using WHO cutoffs: none detected, light (1–4,999 epg) and moderate/heavy (≥5,000 epg), the interaction test for subgroup effects was not statistically significant. The effects for children with moderate or heavy intensity of *A. lumbricoides* infection was 0.12 kg (−0.05, 0.28) which is higher than the effect for those with no detected infection (−0.01 kg [95% CI: −0.11, 0.09]) or those with light infection intensity (0.04 kg, 95% CI: −0.07, 0.15) (Figure S25).

In order to explore the role of *A. lumbricoides* prevalence further, we conducted a meta-regression according to prevalence of *A. lumbricoides* at the study level using aggregate data for all 30 studies available with STH deworming versus placebo. We chose this comparison since it is the comparison with the most data. The results yielded a coefficient of 0.18 (SE, 0.24), \( p = .455, \) 95% CI: −0.313, 0.68) with an adjusted \( R^2 \) of −2.97% (proportion of between-study variance explained by prevalence of ascaris). These results indicate that *A. lumbricoides* prevalence was not a significant predictor of the effectiveness of deworming (Figure 19).

**Height**

Tests for interaction for subgroup effects across *A. lumbricoides* intensity were not statistically significant for weight gain for the NMA. When using cut-offs for intensity of infection for *A. lumbricoides* based on the median distribution across three levels: none detected, lighter intensity (1–1,776 epg), and higher intensity (>1,776 epg), the effect modification for children with higher intensity was 0.04 cm (95% CI: −0.22, 0.30) (Table S15).

For the posthoc direct evidence analysis of STH deworming versus placebo for height gain across three levels of *A. lumbricoides* infection, using WHO cutoffs: none detected, light (1–4,999 epg) and moderate/heavy (≥5,000 epg), the interaction test for subgroup effects was not statistically significant. The effect for children with

---

**TABLE 18 (Continued)**

| Study   | Comparator Cognition outcome | Treatment | Comparator Motor development | Comparator Total cognition | Comparator Total cognition Difference (NMA cov. − No cov.) |
|---------|-------------------------------|-----------|-----------------------------|----------------------------|------------------------------------------------------------|
| Stoltzfus04 | EE (no covariates) Placebo Motor development | Mebendazole (high) + iron Placebo | 0.01 | 0.10 | 0.07 |
| Solon | EE (IPD-NMA covariates) Placebo Motor development | Albenzadole + micronutrients Placebo | 0.34 | 1.19 | −0.51 |
| Solon | EE (IPD-NMA covariates) Placebo Total cognition | Albenzadole + micronutrients Placebo | 0.11 | 0.07 | 0.04 |
| Solon | EE (IPD-NMA covariates) Placebo Total cognition | Micronutrients Placebo | 0.21 | 0.19 | 0.02 |

Abbreviation: cov., covariate; IPD, individual participant data; LCI, lower confidence interval; NMA, network meta-analysis; UCI, upper confidence interval.

*Bold values are statistically significant differences between the intervention and placebo groups.*

FIGURE 19  Meta-regression according to prevalence of *Ascaris lumbricoides* for difference in weight gain at aggregate level
moderate or heavy intensity of A. lumbricoides infection was 0.07 cm (95% CI: −0.07, 0.22) (Figure S26).

Haemoglobin
Tests for interaction for subgroup effects across A. lumbricoides intensity were not statistically significant for change in haemoglobin for the NMA. When using cut-offs for intensity of infection for A. lumbricoides based on the median distribution across three levels: none detected, lighter intensity (1–1,776 epg), and higher intensity (>1,776 epg), the effect modification for children with higher intensity was 0.48 g/L (95% CI: −0.69, 1.66) (Table S15).

For the posthoc analysis of direct evidence of STH deworming versus placebo for haemoglobin across three levels of A. lumbricoides infection, using WHO cutoffs: none detected, light (1–4,999 epg) and moderate/heavy (≥5,000 epg), the interaction test for subgroup effects was not statistically significant. The effect for children with moderate or heavy intensity of A. lumbricoides infection was 0.44 g/L (95% CI: −2.49, 1.60) (Figure S27).

Cognition
Tests for interaction for subgroup effects across A. lumbricoides intensity were not statistically significant for single digit attention scores, math scores, Tamil language scores, processing speed index, working memory index, TIMSS z score, digit forward, digit back, block score and code score (Table S16).

5.12.6 Hookworm, as effect modifier
Two analyses were conducted: (a) NMA using cutoffs based on the distribution of intensity in the sample of three levels and (b) direct evidence analysis using WHO cutoffs for intensity of infection.

Weight
Tests for interaction for subgroup effects in the NMA across hookworm intensity were not statistically significant for weight gain for any comparison. When using cut-offs for intensity of infection for hookworm based on the median distribution across three levels: none detected, lighter intensity (1–384 epg), and higher intensity (>384 epg), the effect modification for children with higher intensity was 0.16 kg (95% CI: −0.07, 0.22) (Figure S26).

For the pairwise meta-analysis of STH deworming versus placebo for weight gain across three levels of hookworm infection using WHO cutoffs: none detected, light (1–1,999 epg) and moderate/heavy (≥2,000 epg), the interaction test for subgroup effects was not statistically significant. The effect for children with moderate or heavy intensity of hookworm infection was −0.53 kg (95% CI: −2.09, 1.03) (Figure S28).

To further assess the role of prevalence of hookworm, we conducted meta-regression using aggregate level data for 23 studies with data on hookworm prevalence for the comparison of STH deworming versus placebo. The proportion of variance explained is 54%, p = .014, showing a positive relationship of weight gain with hookworm infection prevalence (Figure 20).

Height
Tests for interaction for subgroup effects across hookworm intensity were not statistically significant for height for any comparison in the NMA. When using cut-offs for intensity of infection for hookworm based on the median distribution across three levels: none detected, lighter intensity (1–384 epg), and higher intensity (>384 epg), the effect modification for children with higher intensity was 0.20 cm (95% CI: −0.13, 0.52) (Table S15).

For the direct evidence, posthoc analysis of STH deworming versus placebo for height gain across three levels of hookworm infection, using WHO cutoffs: none detected, light (1–1,999 epg) and moderate/heavy (≥2,000 epg), the interaction test for subgroup effects was not statistically significant. The effect for children with moderate or heavy intensity of hookworm infection was −0.17 cm (95% CI: −0.52, 0.18) (Figure S29).

Haemoglobin
Tests for interaction for subgroup effects across hookworm intensity were not statistically significant for change in haemoglobin for any comparison in the NMA. When using cut-offs for intensity of infection for hookworm based on the median distribution across three levels: none detected, lighter intensity (1–384 epg) and higher intensity (>384 epg), the effect modification for children with higher intensity was 3.58 g/L (95% CI: 0.13, 7.02) (Table S15).

For the direct evidence, posthoc analysis of STH deworming versus placebo for haemoglobin across three levels of hookworm infection using WHO cutoffs: none detected, light (1–1,999 epg) and moderate/heavy (≥2,000 epg), the interaction test for subgroup effects was not statistically significant. The effect for children with moderate or heavy intensity of hookworm infection was −0.56 g/L (95% CI: −6.39, 5.27) (Figure S30).

FIGURE 20 Meta-regression of hookworm prevalence at aggregate level for 23 studies with data on STH versus placebo. STH, soil-transmitted helminthiasis
Cognition
Tests for interaction for subgroup effects across hookworm intensity were not statistically significant for any comparison for single digit attention scores, math scores, Tamil language scores, processing speed index, working memory index, TIMSS z score, digit forward, digit back, block score and code score (Table S16).

5.12.7 T. trichiura, as effect modifier
We conducted two analyses: (a) NMA using cutoffs based on the distribution of intensity in the sample of three levels and (b) direct evidence analysis using WHO cutoffs for intensity of infection.

Weight
Tests for interaction for subgroup effects across T. trichiura intensity were not statistically significant for weight gain for any comparison in the NMA. When using cut-offs for intensity of infection for T. trichiura based on the median distribution across three levels: none detected, lighter intensity (1–288 epg), and higher intensity (>288 epg), the effect modification for children with higher intensity was 0.17 kg (95% CI: –0.06, 0.41) (Table S15).

For the direct evidence, posthoc analysis of STH deworming versus placebo for weight gain across three levels of T. trichiura infection using WHO cutoffs: none detected, light (1–999 epg) and moderate/heavy (≥1,000 epg), the interaction test for subgroup effects was not statistically significant. However, the effect for children with moderate or heavy intensity of T. trichiura infection was 0.11 kg (–0.14, 0.35) which was higher than for those with no detected infection (Figure S31).

Height
Tests for interaction for subgroup effects across T. trichiura intensity were not statistically significant for height for any comparison in the NMA models. When using cut-offs for intensity of infection for T. trichiura based on the median distribution across three levels: none detected, lighter intensity (1–288 epg), and higher intensity (>288 epg), the effect modification for children with higher intensity was 0.07 cm (–0.02, 0.34) (Table S15).

For the direct evidence, posthoc analysis of STH deworming versus placebo for height gain across three levels of T. trichiura infection using WHO cutoffs: none detected, light (1–999 epg) and moderate/heavy (≥1,000 epg), the interaction test for subgroup effects was not statistically significant. The effect for children with moderate or heavy intensity of T. trichiura infection was –0.17 cm (–0.52, 0.18) (Figure S32).

Haemoglobin
Tests for interaction for subgroup effects across T. trichiura intensity were not statistically significant for haemoglobin for any comparison in the NMA models. When using cut-offs for intensity of infection for T. trichiura based on the median distribution across three levels: none detected, lighter intensity (1–288 epg), and higher intensity (>288 epg), the effect modification for children with higher intensity was 1.33 g/L (–1.14, 3.81) (Table S15).

For the direct evidence, posthoc analysis of STH deworming versus placebo for change in haemoglobin across three levels of T. trichiura infection using WHO cutoffs: none detected, light (1–999 epg) and moderate/heavy (≥1,000 epg), the interaction test for subgroup effects was not statistically significant. The effect for children with moderate or heavy intensity of T. trichiura infection was 0.33 g/L (–2.99, 3.65) (Figure S33).

Cognition
Tests for interaction for subgroup effects across T. trichiura intensity were not statistically significant for any comparison for single digit attention scores, math scores, Tamil language scores, processing speed index, working memory index, TIMSS z score, digit forward, digit back, block score and code score (Table S16).

5.12.8 Any helminth infection, as effect modifier
Weight
Tests for interaction for subgroup effects across a composite category of intensity of infection for any parasite were not statistically significant for weight gain for any comparison in the NMA-IPD model (Figure S34 and Table S15).

Height
Tests for interaction for subgroup effects across a composite category of intensity of infection for any parasite were not statistically significant for height gain for any comparison (Figure S35 and Table S15).

Haemoglobin
Tests for interaction for subgroup effects across a composite category of intensity of infection for any parasite were not statistically significant for change in haemoglobin for any comparison (Figure S36 and Table S15).

Cognition
Tests for interaction for subgroup effects across a composite category of intensity of infection for any parasite were not statistically significant for any comparison for single digit attention scores, math scores, Tamil language scores, processing speed index, working memory index, TIMSS z score, digit forward, digit back, block score and code score (Table S16).

5.12.9 Anaemia as an effect modifier
Weight
Tests for interaction for subgroup effects across anaemia were not statistically significant for weight gain for any comparison (Figure S37 and Table S15).
Tests for interaction for subgroup effects across anaemia were not statistically significant for height gain for any comparison (Figure 38 and Table S15).

Tests for interaction for subgroup effects across anaemia were not statistically significant for change in haemoglobin for any comparison (Table S15; Figures 21 and S39).

Tests for interaction for subgroup effects across anaemia were not statistically significant for any comparison for single digit attention scores, math scores, Tamil language scores, working memory index, TIMSS z score, digit forward, digit back, block score and code score (Table S16).

We planned to restrict our IPD-NMA to studies conducted 2008 or later. However, we decided that it would be more informative to conduct a meta-regression using aggregate data according to year of publication to include older studies for which we were unable to obtain individual participant datasets.

This analysis shows a negative association, with a greater effect in older studies which was not statistically significant ($p = 0.05$) and explained 7.88% of the variance between studies. The graph shows a concentration of more recent studies with smaller effects on weight gain.

We compared our findings for weight gain, height gain and haemoglobin and cognition to a Cochrane review (Taylor-Robinson et al., 2015) and prior Campbell review, which both used aggregate level data (Table 19). Also, the Welch et al. 2016 review assessed the relationship of aggregate data with prevalence of each type of helminth infection, and found no relationship using two different methods. The findings of this systematic review and IPD-NMA are in agreement with this, using IPD-NMA effect modification tests for subgroup effects, and aggregate data subgroup analysis as well as meta-regression across prevalence of ascaris. Unlike our prior systematic review, we did find a statistically significant relationship with hookworm prevalence and effect on weight gain.

We also compared our findings to Croke et al. meta-analysis (Croke et al., 2016; Table 20). This comparison contains 34 possible effect estimates from 33 studies of STH deworming versus placebo. The meta-analysis by Croke et al. does not include 13 estimates which we have included, two because they are SAT studies (Sarkar et al., 2002; Yap et al. 2014). The remaining studies, it is unclear why they were excluded since no table of excluded studies is provided.

### Table 19: Comparison of results with other recent systematic reviews and meta-analyses

| Review | Taylor-Robinson et al. (2015), Regular frequency STH deworming (2/year) vs. placebo | Welch et al. (2016), Albenza 2/year vs. placebo | Welch et al. (2018) STH deworming vs. placebo |
|--------|----------------------------------------------------------------------------------|------------------------------------------------|-----------------------------------------------|
| Weight gain | 0.08 kg (95% CI: -0.11, 0.27) | 0.09 kg (95% CI: -0.04, 0.2) | IPD-NMA: 0.01 kg (95% CI: -0.08, 0.11) Aggregate level, all studies (received, not received and ineligible due to lack of baseline infection intensity: 0.07 (95% CI: 0.01, 0.13) random effects |
| Height gain | 0.02 cm (95% CI: -0.14, 0.17) | 0.07 cm (95% CI: -0.1, 0.24 cm) | 0.09 cm (95% CI: -0.08, 0.27) |
| Change in haemoglobin | 0.02 g/dL (95% CI: -0.08, 0.04) | Not pooled, concluded there were effects only when combined with micronutrients, iron or praziquantel | 0.32 g/L (95% CI: -0.63, 1.26). |
| Cognition | Little to no effect | 0.23 points on a 100 point scale (95% CI: -0.6, 0.14) | Little to no effect |

Abbreviation: IPD, individual participant data.
### TABLE 20: Comparison of Croke et al. (2016) with data from this review and Welch et al. 2016 systematic review

| Study Reference | Sample size (children) | Welch et al. (2016, 2018) | Croke et al. (2016) |
|-----------------|------------------------|---------------------------|---------------------|
|                  | Effect estimate and 95% CI | Sample size (children) | Weight in meta-analysis (%) | Aggregate data estimate | Weight in meta-analysis (%) | Effect estimate and 95% CI |
| **Included in both, with same estimate and SE** | | | | |
| Alderman 2006 (cluster) | 1,305 | 4.10 | 0.15 (−0.03, 0.33) | 6.02 | 0.15 (−0.02, 0.33) |
| Dossa vs. placebo 2001 | 65 | 1.90 | 0.00 (−0.52, 0.52) | 0.68 | 0.00 (−0.52, 0.52) |
| Gateff 1972 | 140 | 2.70 | 0.35 (−0.03, 0.73) | 2.81 | 0.35 (0.09, 0.60) |
| Gupta 1982 | 39 | 2.90 | 0.03 (−0.32, 0.38) | 1.56 | 0.03 (−0.32, 0.37) |
| Joseph 2015 | 440 | 4.70 | 0.04 (−0.06, 0.14) | 18.40 | 0.04 (−0.06, 0.14) |
| Ostwald 1984 | 45 | 0.90 | 0.70 (−0.18, 1.58) | 0.24 | 0.70 (−0.18, 1.58) |
| Stephenson 1993 | 93 | 2.40 | 0.90 (0.54, 1.26) | 1.41 | 0.90 (0.54, 1.26) |
| Watkins 1996 | 110 | 4.70 | 0.13 (−0.08, 0.34) | 4.27 | 0.13 (−0.08, 0.34) |
| Willett 1979 | 137 | 4.10 | 0.16 (−0.03, 0.35) | 6.67 | 0.16 (−0.01, 0.33) |
| **Included in both, same effect, different SE** | | | | |
| Sur 2005 | 341 | 2.60 | 0.29 (−0.10, 0.68) | 6.11 | 0.29 (0.12, 0.47) |
| **Included in both, different point estimates** | | | | |
| Awasthi 2000 | 387 | 4.70 | 0.04 (−0.06, 0.14) | 8.29 | −0.05 (−0.20, 0.10) |
| Donnen 1998 | 117 | 2.90 | −0.55 (−0.89, −0.21) | 1.73 | −0.45 (−0.78, −0.12) |
| Kruger 1996 | 91 | 3.90 | 0.03 (−0.15, 0.21) | 0.93 | −0.38 (−0.82, 0.06) |
| Liu 2017 (cluster) | 1,028 | 3.50 | 0.06 (−0.20, 0.32) | 2.27 | 0.03 (−0.25, 0.31) |
| Miguel 2004 (cluster) | 9,360 | 3.70 | 0.01 (−0.26, 0.28) | 0.25 | −0.75 (−1.63, 0.10) |
| Nدبазза 2012 | 715 | 4.70 | −0.02 (−0.12, 0.08) | 5.80 | 0.01 (−0.170, 0.19) |
| Wiria 2013 (cluster) | 310 | 2.00 | −0.18 (−0.68, 0.32) | 0.24 | 0.19 (−0.69, 1.06) |
| **Studies included by Welch et al., not by Croke** | | | | |
| Bhoite 2012 (cluster) | 153 | 0.10 | −1.30 (−4.31, 1.71) | Not included |
| Garg 2002 | 181 | 4.40 | 0.02 (−0.13, 0.17) | Not included |
| Huong 2007 | 426 | 4.10 | 0.13 (−0.06, 0.31) | Not included |
| Kirwan 2009 (weight unpublished) | 494 | 4.10 | −0.12 (−0.30, 0.06) | Not included (unpublished) |
| Nga 2009 and 2011 | 122 | 4.60 | 0.05 (−0.07, 0.17) | Not included |
| Olds 1999 | 91 | 2.50 | −0.22 (−0.63, 0.18) | Not included (unpublished) |
| Rousham 1994 (cluster) | 124 | 3.70 | −0.11 (−0.35, 0.13) | Not included |
| Sarkar 2002 (SAT) | 41 | 3.30 | 0.38 (0.09, 0.67) | Not included, screen and treat |
| Solon 2003 | 831 | 3.90 | 0.15 (−0.07, 0.36) | Not included (unpublished) |
| Stoltzfus 2004 (cluster) | 463 | 3.40 | −0.08 (−0.33, 0.16) | Not included |
| Stoltzfus 1997 (cluster) | 1,054 | 3.10 | 0.16 (−0.15, 0.48) | Not included |
| Yap 2014 | 95 | 3.40 | 0.27 (−0.01, 0.56) | Not included, screen and treat |
| **Studies included by Croke, not by Welch et al.** | | | | |
| Awasthi 1995 (2008) | 3,712 (50 clusters) | − | Not included STH + vitamin A vs. vitamin A | 2.19 | 0.98 (0.69, 1.27) |
| Awasthi 2001 | 1,672 (124 clusters) | − | Not included, STH + vitamin A vs. vitamin A | 11.35 | 0.17 (0.04, 0.30) |
| Dossa 2001 (with iron) | 64 | − | Not included, since iron in both arms | 14.09 | 0.00 (−0.27, 0.27) |
| Hall 2006 | 2,659 (80 schools) | − | Not included, STH + vitamin A vs. vitamin A | 14.09 | 0.05 (−0.06, 0.14) |

(Continues)
We excluded four studies where STH was combined with micro-nutrients or iron and compared to micronutrients or iron. This is because of our decision to keep this as a separate treatment comparison. The table below shows that our effect estimate is lower than Croke et al. for both fixed and random effects. Even when we conduct a sensitivity analysis, adding the four studies of STH + micronutrients versus micronutrients, we still have a lower effect estimate than Croke et al. (2016) with a random effects meta-analysis of 0.10 kg (95% CI: 0.03, 0.17) and fixed effects 0.07 (95% CI: 0.04, 0.10).

Our primary analysis was deworming versus placebo (without cointerventions) because it was the closest match to our NMA.

### 5.13.1 Notes for those with different point estimates and standard errors

Awasthi and Pande (2001): We used 1 year data reported in Taylor-Robinson, Maayan, Soares-Weiser, Donegan, and Garner (2012) systematic review. Croke et al. (2016) used 2 year data.

Donnen et al. (1998): we used adjusted estimates reported by Donnen et al. (1998). Croke et al. (2016) used unadjusted estimates provided to the Cochrane authors.

Kruger et al. (1996): Kruger et al. (1996) randomised children to anthelminthic therapy (albendazole 400 mg once at baseline and once 5 months later) versus placebo tablets. In addition, three schools received fortified soup and two received unfortified soup. Taylor-Robinson et al. (2015) and Croke et al. (2016) evaluated the effect of anthelmintics for the children who did not receive fortified soup to avoid the confounding effect of iron (n = 74). Since we considered that the fortified soup and unfortified soup were not randomised, we collapsed across the fortified and unfortified soup conditions, calculating an overall effect for all children randomised to anthelmintics versus placebo (n = 178).

Liu et al. (2017): We used IPD data provided by the authors. Croke et al. (2016) used published mean changes.

Miguel and Kremer (2004): We used data from the public use files for the 1st year of comparison, where we considered Group 1 as STH deworming and Groups 2 and 3 as control. It is not clear which data were used by Croke et al., but they may have had access to different datasets, or used data from the 2nd year of the study.

Ndibazza et al. (2012): We used data from IPD provided by the authors. Croke et al. used mean changes provided by the authors to Welch et al. for the 2016 review.

Wiria et al. (2013): Croke et al. (2016) used a table provided by the authors with baseline weight, and weight at 9 and 21 months, then calculated a change score and associated variance. We were able to replicate this table from the authors. However, we used IPD change score for children with complete data at baseline and 9 months to calculate a change score.

Studies not included in Welch et al. analysis: We did not include four studies in this analysis since they are a comparison of deworming combined with vitamin A versus vitamin A (Awasthi et al., 2008; Awasthi & Pande, 2001; Hall et al., 2006) or STH.
deworming + iron versus iron (Dossa et al., 2001). Because we used a NMA approach, these studies are included in the node for STH + micronutrients or iron compared to micronutrients or iron. In a sensitivity analysis, we included these studies to assess the influence on our results, and our random effects meta-analysis was 0.10 kg (95% CI: 0.03, 0.17). Note: these studies are included in the NMA-IPD presented in this paper if they had baseline infection intensity and provided data (that is, Hall et al. (2006) was included).

6 | DISCUSSION

6.1 | Summary of main results

This IPD NMA and systematic review reinforces findings from previous meta-analyses and the 2017 WHO guidelines on mass deworming that STH deworming alone is insufficient to improve population level child health and cognitive outcomes based on moderate certainty evidence. When we add data obtained for this IPD analysis from unpublished results on weight gain to studies included in our prior meta-analysis, the overall effect across 25 studies of deworming compared to placebo is 0.07 kg (-0.01, 0.13). This effect size is comparable to other published systematic reviews and meta-analyses.

A central issue in deworming debates has been the difficulty of detecting effects when the majority of the population has light or no detectable infection. Our review is unique in its ability to assess effect modification using IPD. Effect modification analyses across intensity of infection, using WHO cutoffs, suggest that deworming may slightly increase weight in children with moderate to heavy intensity infections of A. lumbricoides or T. trichiura (very low certainty).

At the population level, for weight gain, we found little effect for STH deworming versus placebo with our NMA IPD results (0.01 kg; 95% CI: -0.08, 0.11) with moderate quality evidence, and results for all other comparisons were similar. For height, we found little effect on height (0.09 cm; 95% CI: -0.08, 0.27) with moderate quality evidence and similar effects across all comparisons. For haemoglobin, we found little effect of deworming for STH (0.32, 95% CI: -0.63, 1.26) (low certainty). Deworming with praziquantel resulted in an increase in haemoglobin compared to placebo of 1.85 g/L (95% CI: 0.53, 3.18). Similarly, deworming with praziquantel combined with iron or micronutrients increased haemoglobin (2.72 g/L, 95% CI: 1.05, 4.40), iron or micronutrients with STH deworming increased haemoglobin (1.98 g/L, 95% CI: 0.74, 3.21) compared to placebo (low certainty evidence). For cognition, studies reported no effects of any types of deworming on short term attention measures such as digit forward or processing speed or measures of child development.

Subgroup analysis were considered at very low certainty due to imprecision of results. There were no statistically significant subgroup effects across age, sex, infection intensity for any type of STH infection using median distribution of intensity, BMI for age, height for age or anaemia (moderate certainty). For subgroup analysis using WHO cutoffs and direct evidence, children with moderate to heavy A. lumbricoides or hookworm infection, deworming may slightly increase weight but not height or haemoglobin compared to children with no detected infection or light infection intensity (very low certainty evidence).

These findings were robust to sensitivity analyses across risk of bias and effectiveness of studies at reducing infection prevalence as well as differences in the model structure, adjustment for covariates, risk of bias and the use of multiple imputation for missing data.

Clinical importance of weight and height for STH deworming needs to be put in the context of the children in these studies, where 33% of children were stunted, 54% were anaemic, 41% were infected with hookworm, 48% with A. lumbricoides, 53% with trichuris and 73% were over 5 years of age. According to WHO growth standards, weight gain for children aged 7 years is approximately 2 kg in 12 months. Therefore, the 95% CI observed in our analysis of -0.08 to 0.11 kg for STH versus placebo is equivalent to -4% to +5.5% relative to the expected weight gain over this time period for these children. This is much smaller than effects of other nutritional programmes such as schoolfeeding which increases weight gain by about 0.39 kg annually (Kristjansson et al., 2007). We are moderately certain that further research will not change this estimate. Uncertainty arises since we were unable to obtain data from all published trials.

Clinical importance of haemoglobin effects need also to be considered in light of the average haemoglobin level of these children, and the settings in which they live. Almost half (46%) of our sample was anaemic, defined as haemoglobin below 115 g/L. STH deworming alone compared to placebo had small effects on haemoglobin (0.32 g/L) but STH deworming combined with micronutrients or iron compared to placebo had larger effects (1.98 g/L). As a comparison, iron supplementation alone for children <12 years of age was found to increase haemoglobin by approximately 5 g/L (De-Regil et al., 2011).

We were successful in retrieving 14% (2/14 studies) for deworming for schistosomiasis. As a result, we were unable to conduct our planned analysis of deworming for schistosomiasis.

6.2 | Overall completeness and applicability of evidence

For STH deworming, we received data for 19 studies with 31,945 participants of an eligible 41 studies with 40,132 participants for studies of STH deworming. Fifteen of the 19 studies were published in the last 15 years.

We had sufficient participants in each level of our planned effect modifier analyses to run all of our planned effect modification analyses using the base case evidence network. Although there were no statistically significant differences across infection intensity levels, these were limited due to the paucity of children with moderate to heavy infection intensity in our sample (<13%). Furthermore, the upper CIs included potentially important effects of up to 460 g for weight and 7 g/L for haemoglobin. In direct evidence comparisons using WHO cutoffs, we also did not find statistically significant interaction across intensity of infection, however, there were larger
effects on weight gain for children with moderate or heavy intensity infections of *A. lumbricoides* or *T. trichiura*. For prevalence of *A. lumbricoides* and hookworm, we also assessed whether there was a relationship between prevalence and effects on weight using meta-regression for aggregate data for all studies with weight data for STH deworming versus placebo. These analyses did not show a relationship with *A. lumbricoides* prevalence at the study level. There was an association of higher hookworm prevalence with effect on weight. These meta-regressions must be interpreted with caution since they are using data at the aggregate level (Debray et al., 2018).

We conducted an extensive search of electronic databases, with advice from the Campbell Collaboration International Development Group information scientist. We screened 16,613 articles and updated this search to March 27, 2018. We report the systematic review according to the reporting guidelines for IPD meta-analysis (PRISMA‐IPD) and network-meta-analysis (PRISMA NMA).

We published and followed an a priori protocol (Welch et al., 2018). Our systematic review and IPD analysis was approved by the Research Ethics Boards at SickKids and Bruyere Research Institute. We developed a data sharing agreement that was signed by all studies that contributed data. Study authors were invited to join the Investigators’ Collaborative, participate in meetings and contribute to the final report. Our process to developing the evidence network was driven by consultation with our expert Advisory board which included statistical, parasitology and nutrition expertise. We tested our assumptions, model structure and statistical methods using sensitivity analyses.

The studies were conducted in a range of low and middle income countries in settings with predominately poor sanitation with a range of prevalence of STH in children aged from 6 months to 17 years. The prevalence of *A. lumbricoides* infections in our base case sample (14 studies with sufficient data for multiple imputation) was 52% (range, 9–93%), hookworm 45% (range, 1–94%) and *T. trichiura* 52% (range, 9–96%). Less than 15% of children had an infection intensity considered moderate or heavy for *A. lumbricoides*, *T. trichiura* or hookworm, according to the WHO criteria in our sample. Our dataset included 2,448 children <5 years of age in our main models (18% of the sample).

Our data suggest that there is publication bias in the deworming literature with failure to report growth data since we obtained weight and height data from eight studies which had not previously reported these (Beasley et al., 1999; Beasley, 1995; Friis et al., 2003; Ebenezer et al., 2013; Kirwan et al., 2009; Le Huong et al., 2007; Rohner et al., 2010; Solon et al., 2003). We also report cognition data that was not previously published from one study (Rohner et al., 2010). Given our findings of selective outcome reporting, it is still possible that there are additional older studies with negative findings.

We compared the effect sizes observed in the studies that we retrieved to those which were excluded (due to missing baseline infection intensity) or which were unable to obtain from the trial authors (due to lost datasets, administrative hurdles or nonresponse from the authors). We found that the test for interaction for subgroup differences was not statistically significant for weight, height or haemoglobin, but the effect on weight was higher in the studies which were not obtained, which were mostly older studies.

For schistosomiasis deworming, we received only two of 14 eligible studies. We decided that meta-analysis of these two studies would be misleading and did not pursue IPD meta-analysis for schistosomiasis deworming. We did include nodes in our evidence network for combinations of schistosomiasis deworming and STH deworming, but these had relatively fewer studies and participants.

Small amounts of calories were provided in three studies in the form of unfortified or fortified biscuits (Nga et al., 2009), noodles (Le Huong et al., 2007) or beverage (Solon et al., 2003). In each of these studies, the comparator groups received the unfortified food or beverage. We did not identify any studies that looked at providing substantive meals or snacks with deworming. Thus, we cannot draw conclusions on the effects of deworming when combined with feeding programmes in comparison to not providing feeding.

### 6.3 Quality of the evidence

We included only RCTs. About 40% of trials did not provide enough information to assess adequacy of randomisation and allocation concealment. We considered the included studies were at overall low risk of bias. The quality of evidence as assessed using the GRADE framework was moderate across all outcomes and comparisons for the main effects. Quality of evidence was downgraded because of uncertainty about selective reporting bias across the evidence base, and the fact that we were not able to obtain data from all eligible studies. Subgroup effect analyses were judged at very low certainty due to imprecision and inability to obtain all eligible studies.

Sensitivity analyses across adequacy of allocation concealment were congruent with our main findings for weight, height and haemoglobin for all comparisons.

### 6.4 Limitations and potential biases in the review process

One limitation of this review is that we did not receive data from all eligible studies. We compared published results of the studies received for STH deworming versus placebo with the studies that were not received and those that were not eligible to assess the potential influence of these missing studies on our findings. The test for interaction was not statistically significant but the effect on weight gain overall was larger in studies that were not received, which limits the ability of this analysis to assess the overall, population level effects. However, this should not affect the effect modification analyses since these are based on individual level covariates. There was no trend in effect size or direction across the year of publication for weight, height or haemoglobin.

The assumptions of transitivity and consistency were assessed and considered plausible by assessing distribution of effect modifiers, assessing within comparison heterogeneity in direct evidence and by comparing direct and indirect evidence.
Another limitation is that different diagnostic tools with different measuring properties including Kato-Katz, polymerase chain reaction (PCR) and other techniques, were used for assessing infection intensity across the studies and may lead to measurement error. Only one study used PCR, and we used its infection intensity estimates in analyses with other studies, recognising that there may be differences in sensitivity of these tests.

Cognitive outcomes are measured using diverse tools and some are translated for use in these studies. For this reason we presented each cognitive outcome for each study separately without combining them in a meta-analysis. This limits the ability to combine results across studies thus these analyses are under-powered for cognitive outcomes.

We were unable to assess effect modification for infection intensity using the WHO cutoffs for moderate or heavy intensity using our NMA model because <15% of children in our sample met criteria for being moderately to heavily infected, thus the models failed to converge when we used the WHO cutoffs for moderate and heavy intensity infection. To further investigate the importance of infection intensity, we conducted subgroup analysis using the WHO cutoffs for each infection type (none detected, light and moderate/heavy) for the direct evidence of STH deworming versus placebo. The test for interaction for subgroup effects across infection intensity for STH deworming versus placebo for weight, height or haemoglobin was not statistically significant. However, the effect of deworming was higher for weight gain for children with moderate/heavy infection of *A. lumbricoides* and *T. trichuria*, compared to children with light intensity infections or no detected infection. These subgroup analyses were considered very low certainty evidence due to imprecision.

The study durations were short with a median duration of 12 months (ranging from 4 to 45 months) and this may have limited our ability to detect changes in height or weight gain. However, since two of the earlier studies mentioned previously with large effects on weight (Stephenson et al., 1989, 1993) were only 6 and 8 months in duration, we consider that the study durations of these studies was sufficient to assess differences in weight gain. It is unlikely that these study durations are sufficient to assess differences in linear growth. Single dose trials of short duration may not be able to detect positive effects due to high re-infection rates in endemic areas.

In our collapsed model, we collapsed across frequency of deworming which limits our ability to assess whether high frequency STH deworming is more effective than regular frequency deworming. As described above, our preliminary models with frequency of administration as separate nodes did not show differences in effects on weight, height or haemoglobin between high frequency and regular frequency deworming.

Two studies in Kenya have shown large effects on weight gain of 1 kg or more (Stephenson et al., 1989, 1993). The reason for these large effects is unclear. Analysis of heterogeneity led us to exclude the Stephenson et al. (1989) study due to baseline imbalance in a prior systematic review (Welch et al., 2016). The conditions in which those two trials were carried out may have been different from other trials, including characteristics such as intensity of infection, sanitation, and participant and investigator adherence to protocols. However, 25 other studies are available on STH versus placebo, and when all are combined, the overall effect in our analyses is 70 g.

The older studies of deworming suggested stronger effects on nutrition and other health outcomes than we have found in our analysis. Given that stunting is associated with adverse health and cognitive outcomes that implied (since deworming drugs are inexpensive) that deworming is cost-effective. However, our study would cast doubt on this, since at moderate levels of infection, we could not discern significant impacts on key nutrition outcomes such as stunting and wasting. Our systematic review cannot predict outcomes and cost-effectiveness for chemoprophylaxis where infection is severe, since we had <2% of our sample with heavy intensity infections.

Our study did not look at school attendance which has been used for previous cost-effectiveness analysis of deworming. There has been an intense debate on this topic where an independent replication identified smaller benefits than previously thought (Aiken, Davey, Hargreaves, & Hayes, 2015; Hargreaves, Aiken, Davey, & Hayes, 2015; Hicks, Kremer, & Miguel, 2015). Also, our prior systematic review found an average effect on school attendance of 1% (95% CI: −1.3%) (Welch et al., 2016). We also identified problems with the methods of measuring school attendance in these studies.

The implication is that the cost-effectiveness/cost benefit of deworming on the basis of school attendance is not proven.

The exclusion of studies with <100 participants may lead to small study bias. However, only three studies had <100 participants; including them would not affect the main analyses or effect modification analyses.

### 6.5 Agreements and disagreements with other studies or reviews

A Cochrane review (Taylor-Robinson et al., 2015) and Campbell review (Welch et al., 2016) on mass deworming for children both concluded there was little to no effect on weight and height for STH deworming. The effects observed in Taylor-Robinson et al. (2015) were a mean difference of 0.08 kg (95% CI: −0.11, 0.27) on weight, a mean difference of 0.02 cm (95% CI: −0.14, 0.17) on height and a mean difference of 0.02 g/dL, 95% CI: −0.08, 0.04) on haemoglobin for regular treatment, and little to no effect on formal tests of cognition (Taylor-Robinson et al., 2015). In Welch et al. (2016), the effects of Albendazole twice per year were 0.09 kg (95% CI: −0.04, 0.2), 0.07 cm (95% CI: −0.1, 0.24 cm), short term cognition −0.23 points on a 100 point scale (95% CI: −0.6, 0.14). Haemoglobin effects were not combined across studies in Welch et al., but the individual study results are consistent with our finding that there are robust effects on haemoglobin only when iron, micronutrients or praziquantel are combined with STH deworming.

Our findings for STH deworming versus placebo for height, cognition and haemoglobin are similar to these two prior reviews. Our IPD-NMA effect on weight gain of 0.01 kg (95% CI: −0.08, 0.11)
is lower than these reviews, and is likely due to not being able to retrieve data from all eligible studies. Our meta-regression of year of publication and weight gain did not show a statistically significant effect of year of publication, but this must be interpreted with caution since metaregression suffers from low power and was based on aggregate data. The smaller effect seen in our analysis may be related to publication bias in the previous reviews since we obtained unpublished data which is known to be associated with negative findings (defined as smaller effects or nonstatistically significant; Hopewell, Loudon, Clarke, Oxman, & Dickersin, 2009) and that we did not receive data from all available studies.

Our finding on weight gain with our IPD-NMA of 0.01 kg is considerably smaller than in the meta-analysis by Croke et al. (2016) on weight gain (http://www.nber.org/papers/w22382.pdf), which found an average overall effect on weight gain of 0.134 kg (95% CI: 0.031, 0.236). When comparing our analyses of direct evidence from all studies with STH deworming versus placebo (including both studies for which we received IPD and studies which did not contribute IPD), we also found a smaller effect size than Croke et al. of 0.07 kg (95% CI: 0.01, 0.13) on weight with random effects. Our finding that there were no subgroup effects across infection intensity or association of effect size with prevalence do not agree with Croke et al.’s findings that the effect on weight was higher for studies with >20% prevalence (0.148 kg, 95% CI: 0.039, 0.2225558). Much of the difference in our findings across prevalence and intensity of infection may be due to the fact that NMA-IPD has better power to detect subgroup differences than aggregate level subgroup analyses or meta-regression (Dagne et al., 2016).

7 | AUTHORS’ CONCLUSIONS

7.1 | Implications for policy

The policy implications are that deworming alone is insufficient to achieve improvements in population-level growth, nutritional status and cognition. Based on the totality of evidence from three prior systematic reviews and new data from IPD previously unpublished, average effects of mass deworming on child nutritional status and cognition are small at the population level (moderate certainty). Effects are higher for children with moderate to heavy intensity infections thus mass deworming may be beneficial in areas with heavy intensity infections. In areas with predominantly lighter infections, effects are smaller thus policymakers and programmers need to explore other policy options to improve child health and nutrition in these areas.

7.2 | Implications for research

IPD analyses such as this have greater power to investigate effect modifiers, but are currently limited by the time and resources needed to seek data from all eligible studies and the limited availability of such data. There is an urgent need for open data from all research studies. Our analyses were limited by obtaining only 46% of eligible studies, mostly conducted in the last 15 years, which could be mitigated by having all data from prospectively registered trials available in open data repositories, as called for by the Alltrials campaign.

The quality of evidence is rated as moderate for our findings, mainly due to the possibility of selective reporting and publication bias in the body of literature. Further research to obtain additional unpublished data on growth and cognition could change our findings. For schistosomiasis deworming, we were unable to obtain the majority of studies, thus we did not carry out these analyses.

Further short-term studies of STH deworming in lightly infected populations are not likely to change the certainty or sizes of effects observed in this systematic review or in other systematic reviews of deworming.

Ideally, in the design of studies, duplicate methods to measure exposure and outcome in a reliable way would be important. For example, future studies could use more sensitive diagnostic tools (e.g., PCR). Also, for cognition, proper cultural translations and validation of measurement tools are important.

ACKNOWLEDGMENTS

We would like to thank Celia Holland for being part of our Advisory board and providing comments on interim results; Nilanthis de Silva for being part of the investigator team; Andrew Hall for advice and attending our investigator team meetings; Rebecca Stoltzus and James Tielsch for sharing data; Jessica Trawin and Christine Mathew, who contributed to data collection on preparation and Jordan Bernick who contributed to the analysis. We are co-publishing this review in the Journal of Development Effectiveness (JDEFF).

ROLES AND RESPONSIBILITIES

V. W., E. G., A. H., A. R., and G. A. W. had full access to the data and take responsibility for the accuracy of data analyses. Concept and design: Z. B., M. G., S. C., V. W., G. A. W., and P. A.: Horton, Black, Tugwell, Hollingsworth, Holland. Acquisition of data: V. W., E. G. and C. M. Acquisition of data: V. W., E. G. and C. M. Drafting of manuscript: V. W. and E. G. Critical revision of content: all authors. Statistical analysis: V. W., A. H. and A. R., O. D. Obtained funding: Z. B., M. G., G. A. W., and V. W.

SOURCES OF SUPPORT

This review is funded by the Bill and Melinda Gates Foundation (funding reference number: OPP1140742).

DECLARATIONS OF INTEREST

Michelle Gaffey, Robert Black, Deirdre Hollingsworth, Sue Horton, Paul Arora, Alison Riddle, Rehana Salam, Simon Cousens, Omar Dewidar have no conflict of interest, financial or otherwise that may influence judgments made in this review.

Celia Holland is a co-author and principal investigator on a randomised trial of deworming: Kirwan et al. 2009.
Vivian Welch, Elizabeth Ghogomu, Alomgir Hossain, Zulfi Bhutta, Peter Tugwell and George Wells are authors of the Campbell systematic review and NMA of mass deworming for children (Welch et al. 2016). Vivian Welch is editor-in-chief of the Campbell Collaboration.

PLANS FOR UPDATING THE REVIEW

This review will be updated if funds become available.

REFERENCES

References to included studies

Beasley, N. M., Tomkins, A. M., Hall, A., Kihamia, C. M., Lorri, W., Nduma, B., ... Bundy, D. A. (1999). The impact of population level deworming on the haemoglobin levels of schoolchildren in Tanga, Tanzania. Tropical Medicine and International Health, 4(11), 744–750.

Beasley, N. M. R. (1995). A study of parasitic helminth infection and iron deficiency in school age children: Population distribution and dynamics of interaction (Doctoral dissertation). University of Oxford.

Ebenezer, R., Gunawardena, K., Kumarendran, B., Pathmeswaran, A., Jukes, M. C., Drake, L. J., & de Silva, N. (2013). Cluster-randomised trial of the impact of school-based deworming and iron supplementation on the cognitive abilities of schoolchildren in Sri Lanka's plantation sector. Tropical Medicine and International Health, 18(8), 942–951. https://doi.org/10.1111/tmi.12128

Friis, H., Mwaniki, D., Omundi, B., Muniu, E., Thiong’o, F., Ouma, J., ... Michaelsen, K. F. (2003). Effects on haemoglobin of multi-micronutrient supplementation and multi-helmint chemotherapy: A randomised, controlled trial in Kenyan school children. European Journal of Clinical Nutrition, 57(4), 573–579.

Hall, A., Hanh, T., Farley, K., Quynh, T., & Valdivia, F. (2006). An evaluation of the impact of a school nutrition program in Vietnam. Public Health Nutrition, 10(8), 819–826.

Kirwan, P., Asaolu, S. O., Molloy, S. F., Abiona, T. C., Jackson, A. L., & Holland, C. V. (2009). Patterns of soil-transmitted helminth infection and impact of four-monthly albendazole treatments in preschool children from semi-urban communities in Nigeria: A double-blind placebo-controlled randomised trial. BMC Infectious Diseases, 9(1), 20.

Kirwan, P., Jackson, A. L., Asaolu, S. O., Molloy, S. F., Abiona, T. C., Bruce, M. C., ... Holland, C. V. (2010). Impact of repeated four-monthly anthelmintic treatment on Plasmodium infection in preschool children: A double-blind placebo-controlled randomised trial. BMC Infectious Diseases, 10(1), 277.

Le Huong, T., Brouwer, I. D., Nguyen, K. C., Burema, J., & Kok, F. J. (2007). The effect of iron fortification and de-worming on anaemia and iron status of Vietnamese schoolchildren (Randomised Controlled Trial Research Support, Non-U.S. Gov’t). British Journal of Nutrition, 97(5), 955–962. https://doi.org/10.1017/S0007114507065909

Liu, C., Lu, L., Zhang, L., Luo, R., Sylvia, S., Medina, A., ... Zhu, T. (2017). Effect of deworming on indices of health, cognition, and education among schoolchildren in rural China: A cluster-randomized controlled trial. The American Journal of Tropical Medicine and Hygiene, 96(6), 1478–1489.

Miguel, E., & Kremer, M. (2004). Worms: Identifying impacts on education and health in the presence of treatment externalities. Econometrica, 72(1), 159–217.

Ndbizza, J., Mpairwe, H., Webb, E. L., Mawa, P. A., Nampijja, M., Muhangi, L., ... Akello, F. (2012). Impact of anthelmintic treatment in pregnancy and childhood on immunisations, infections and eczema in childhood: A randomised controlled trial. PLOS One, 7(12), e50325.

Nga, T. T., Winichagoon, P., Dijkhuizen, M. A., Khan, N. C., Wasantwisut, E., Furr, H., & Wieringa, F. T. (2009). Multi-micronutrient-fortified biscuits decreased prevalence of anaemia and improved micronutrient status and effectiveness of deworming in rural Vietnamese school children. The Journal of Nutrition, 139(5), 1013–1021.

Nga, T. T., Winichagoon, P., Dijkhuizen, M. A., Khan, N. C., Wasantwisut, E., & Wieringa, F. T. (2011). Decreased parasite load and improved cognitive outcomes caused by deworming and consumption of multi-micronutrient fortified biscuits in rural Vietnamese schoolchildren. American Journal of Tropical Medicine and Hygiene, 85(2), 333–340. https://doi.org/10.4269/ajtmh.2011.10-0651

Olds, G. R., King, C., Hewlett, J., Olveda, R., Wu, G., Ouma, J., & Reeve, P. (1999). Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. The Journal of infectious diseases, 179(4), 996–1003.

Rohner, F., Zimmermann, M. B., Amon, R. J., Yonatsouo, P., Tschanzn, A. B., NGoran, E. K., ... Hurrell, R. (2010). In a randomised controlled trial of iron fortification, anthelmintic treatment, and intermittent preventive treatment of malaria for anaemia control in Ivorian children, only anthelmintic treatment shows modest benefit (Randomised Controlled Trial Research Support, Non-U.S. Gov’t). Journal of Nutrition, 140(2), 635–641.

Rousham, E. K., & Mascie-Taylor, C. G. N. (1994). An 18-month study of the effect of periodic anthelmintic treatment on the growth and nutritional status of pre-school children in Bangladesh. Annals of Human Biology, 21(4), 315–324. https://doi.org/10.1080/0301446940003322

Northrop-Clewes, C. A., Rousham, E. K., Mascie-Taylor, C. N., & Lunn, P. G. (2001). Anthelmintic treatment of rural Bangladeshi children: Effect on host physiology, growth, and biochemical status. The American Journal of Clinical Nutrition, 73(1), 53–60.

Solon, F. S., Sarol, J. N., Jr., Bernardo, A. B. I., Solon, J. A. A., Mehanho, S., Sanchez-Fermin, L. E., ... Juhlin, K. D. (2003). Effect of a multiple-micronutrient-fortified fruit powder beverage on the nutrition status, physical fitness, and cognitive performance of schoolchildren in the Philippines (Randomised Controlled Trial Research Support, Non-U.S. Gov’t). Food and Nutrition Bulletin, 24(4 Suppl), S129–S140.

Stoltzfus, R. J., Albonico, M., Tielsch, J. M., Chwaya, H. M., & Savioli, L. (1997). School-based deworming program yields small improvement in growth of Zanzibari school children after one year. The Journal of Nutrition, 127(11), 2187–2193.

Stoltzfus, R. J., Albonico, M., Chwaya, H. M., Tielsch, J. M., Schulze, K. J., & Savioli, L. (1998). Effects of the Zanzibar school-based deworming program on iron status of children. American Journal of Clinical Nutrition, 68(1), 179–186.

Stoltzfus, R. J., Kvalsvig, J. D., Chwaya, H. M., Mon tresor, A., Albonico, M., Tielsch, J. M., ... Pollitt, E. (2001). Effects of iron supplementation and anthelmintic treatment on motor and language development of preschool children in Zanzibar: Double blind, placebo controlled study. BMJ, 323(7326), 1389–1393.

Stoltzfus, R. J., Chwaya, H. M. Montresor, A., Tielsch, J. M., Jape, J. K., Albonico, M., & Savioli, L. (2004). Low dose daily iron supplementation improves iron status and appetite but not anaemia, whereas quarterly anthelmintic treatment improves growth, appetite and anaemia in Zanzibari preschool children. The Journal of Nutrition, 134(2), 348–356.

Wiria, A. E., Hamid, F., Wannmes, L. J., Kaisar, M. M. M., May, L., Prasetyani, M. A., ... Yazdanaksh, M. (2013). The effect of three-monthly albendazole treatment on malarial parasitemia and allergy: A household-based cluster-randomised, double-blind, placebo-controlled trial. PLOS One, 8(3), e57899.

Yap, P., Wu, F. W., Du, Z. W., Hattendorf, J., Chen, R., Jiang, J. Y., ... Steinmann, P. (2014). Effect of deworming on physical fitness of school-aged children in Yunnan, China: A double-blind, randomized, placebo-controlled trial. PLOS Neglected Tropical Diseases, 8(7), e2983.
References to STH studies that did not provide data

Beach, M. J., Streit, T. G., Addiss, D. G., Prospere, R., Roberts, J. M., & Lammie, P. J. (1999). Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian schoolchildren. *The American Journal of Tropical Medicine and Hygiene*, 60(3), 479–486.

Donnen, P., Brasseur, D., Dramaix, M., Vertongen, F., Zihindula, M., Muhamiriza, M., & Henriart, P. (1998). Vitamin A supplementation but not deworming improves growth of malnourished preschool children in eastern Zaire. *Journal of Nutrition*, 128(8), 1320–1327.

Dossa, R. A., Ategbo, E. A., Koning, F. L., Raaij, J. M., & Hautvast, J. G. (2001). Impact of iron supplementation and deworming on growth performance in preschool Beninese children. *European Journal of Clinical Nutrition*, 55(4), 223–228.

Fox, L. M., Furness, B. W., Haser, J. K., Desire, D., Brissau, J. M., Milord, M. D., ... Beach, M. J. (2005). Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of *Wuchereria bancrofti* and intestinal helminth infections in Haitian children. *The American Journal of Tropical Medicine and Hygiene*, 73(1), 115–121.

Garg, R., Lee, L. A., Beach, M. J., Wamae, C. N., Ramakrishnan, U., & Streit, T. G., Addiss, D. G., Prospere, R., Roberts, J. M., ... & Welch ET AL. Greenberg, B. L., Gilman, R. H., Shapiro, H., Gilman, J. B., Mondal, G., Maksud, M., ... Chowdhury, J. (1991). Single dose piperazine therapy for *Ascaris lumbricoides*: An unsuccessful method of promoting growth. *The American Journal of Clinical Nutrition*, 34(11), 2508–2516.

Haridijaja, P., Bonang, E., Suyardi, M. A., Abidin, S. A., Ismid, I. S., & Margono, S. S. (1998). The effect of intervention methods on nutritional status and cognitive function of primary school children infected with *Ascaris lumbricoides*. *The American Journal of Tropical Medicine and Hygiene*, 59(5), 791–795.

Hadj, V., Satriono, N., Abadi, K., & Stephenson, L. S. (1997). Relationships between soil-transmitted helminthiases and growth in urban slum schoolchildren in Ujung Pandang, Indonesia. *International Journal of Food Sciences and Nutrition*, 48(2), 85–93.

Hasque, R., Ahmed, T., Wahed, M. A., Mondal, D., Rahman, A. H., & Albert, M. J. (2010). Low-dose β-carotene supplementation and deworming improve serum vitamin A and vitamin E concentrations in preschool children of Bangladesh. *Journal of Health, Population, and Nutrition*, 28(3), 230.

Henry, F. J. (1988). Reinfestation with *Ascaris lumbricoides* after chemotherapy: A comparative study in three villages with varying sanitation. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 82(3), 460–464.

Jinabhai, C. C., Taylor, M., Coutoudis, A., Coovadia, H. M., Tomkins, A. M., & Sullivan, K. R. (2001a). Epidemiology of helminth infections: Implications for parasite control programmes, a South African perspective. *Public Health Nutrition*, 4(6), 1211–1219.

Jinabhai, C. C., Taylor, M., Coutoudis, A., Coovadia, H. M., Tomkins, A. M., & Sullivan, K. R. (2001b). A randomised controlled trial of the effect of anthelminthic treatment and micronutrient fortification on health status and school performance of rural primary school children. *Annals of Tropical Paediatrics*, 21(4), 319–333.

Kloetzel, K., Merluzzi Filho, T. J., & Kloetzel, D. (1982). Ascaris and malnutrition in a group of Brazilian children—a follow-up study. *Journal of Tropical Pediatrics*, 28(1), 41–43.

Koroma, M. M., Williams, R. A., de la Haye R. R., & Hodges, M. (1996). Effects of albendazole on growth of primary school children and the prevalence and intensity of soil-transmitted helminths in Sierra Leone. (Letter). *Journal of Tropical Pediatrics*, 42(6), 371–372.

Lai, K. P., Kaur, H., Mathias, R. G., & Ow-Yang, C. K. (1995). Ascaris and *Trichuris* do not contribute to growth retardation in primary school children. *The Southeast Asian Journal of Tropical Medicine and Public Health*, 26(2), 322–328.

Michaelsen, K. F. (1985). Hookworm infection in Kweneng District, Botswana. A prevalence survey and a controlled treatment trial. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 79(6), 848–851. https://doi.org/10.1016/0035-9203(85)90136-1

Ostwald, R., Fitch, M., Arnhold, R., Shield, J., Louie, D., Kilner, J., & Kimber, R. (1984). The effect of intestinal parasites on nutritional status in well-nourished school-age children in the highlands of Papua New Guinea. *Nutrition Reports International*, 30(6), 1409–1421.

Pust, R. E., Binns, C. W., Weinhold, D. W., & Martin, J. R. (1985). Palm oil and pyranatel as child nutrition mass interventions in Papua New Guinea (Comparative Study Research Support, Non-U.S. Gov’t). *Tropical and Geographical Medicine*, 37(1), 1–10.

Stephenson, L. S., Latham, M. C., Kurz, K. M., Kinoti, S. N., & Brigham, H. (1989). Treatment with a single dose of albendazole improves growth of Kenyan schoolchildren with hookworm, *Trichuris trichiura*, and *Ascaris lumbricoides* infections. *The American Journal of Tropical Medicine and Hygiene*, 41(1), 78–87.

Taylor, M., Jinabhai, C. C., Couper, I., Kleinschmidt, I., & Jogessar, V. B. (2001). The effect of different anthelmintic treatment regimens combined with iron supplementation on the nutritional status of schoolchildren in KwaZulu-Natal, South Africa: A randomised controlled trial. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 95(2), 211–216.

Watkins, W. E., Cruz, J. R., & Pollitt, E. (1996). The effects of deworming on indicators of school performance in Guatemala. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 90(2), 156–161.

Watkins, W. E., & Pollitt, E. (1996). Effect of removing *Ascaris* on the growth of Guatemalan schoolchildren. *Pediatrics*, 97(6 Pt 1), 871–876.

Willett, W. C., Kilama, W. L., & Kihamia, C. M. (1979). Ascaris and growth rates: A randomised trial of treatment. *American Journal of Public Health*, 69(10), 987–991.

References to schistosomiasis studies

Assis, A. M., Barreto, M. L., Prado, M. S., Reis, M. G., Parraga, I. M., & Blanton, R. E. (1998). Schistosoma mansoni infection and nutritional status in schoolchildren: A randomized, double-blind trial in northeastern Brazil. *The American Journal of Clinical Nutrition*, 68(6), 1247–1253.

Bhargava, A., Jukes, M., Lambo, J., Kihania, C. M., Lorri, W., Nokes, C., ... Bundy, D. (2003). Anthelmintic treatment improves the haemoglobin and serum ferritin concentrations of Tanzanian schoolchildren. *Food and Nutrition Bulletin*, 24(4), 332–342.

Befidi-Mengue, R. N., Ratard, R. C., D’Alessandro, A., Rice, J., Befidi-Mengue, R., Kouemeni, L. E., & Cline, B. L. (1992). The impact of *Schistosoma haematobium* infection and of praziquantel treatment on the growth of primary school children in Bertoua, Cameroon. *The Journal of Tropical Medicine and Hygiene*, 95(6), 404–409.

Branchini, M. L. M., Pedro, R. D. J., Dias, L. C., & Deberaldini, E. R. (1982). Double-blind clinical trial comparing praziquantel with oxamniquine in the treatment of patients with schistosomiasis mansoni. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 24(5), 315–321.

Clarke, V. D. V., Weber, M. C., & Blair, D. M. (1973). Suppressive therapy in the control of bilharziiasis: A comparative trial in African schoolchildren. *Ferrari, M. L. A., Coelho, P. M. Z., Antunes, C. M. F., Tavares, C. A. P., & Da Cunha, A. S. (2003). Efficacy of oxamniquine and praziquantel in the treatment of Schistosoma mansoni infection: A controlled trial. *Bulletin of the World Health Organization*, 81, 190–196.*
Ibrahim, A. M. A. (1980). Evaluation of oxamniquine in the treatment of S. mansoni infection among Sudanese patients. East African Medical Journal, 57(8), 566–573.

Kardaman, M. W., Fenwick, A., Daifalla, A. A., & Dixon, H. G. (1985). Treatment with praziquantel of schoolchildren with concurrent Schistosoma mansoni and S. haemobium infections in Gezira, Sudan. The Journal of Tropical Medicine and Hygiene, 88(2), 105–109.

Lambertucci, J. R., Greco, D. B., Pedroso, E. R. P., da, M. O., Rocha, C., Salazar, H. M., & de Lima, D. P. (1982). A double blind trial with oxamniquine in chronic schistosomiasis mansoni. Transactions of the Royal Society of Tropical Medicine and Hygiene, 76(6), 751–755.

Olds, G. R., King, C., Hewlett, J., Olveda, R., Wu, G., Ouma, J., & Reeve, P. (1999). Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. The Journal of Infectious Diseases, 179(4), 996–1003.

Omer, A. H. (1981). Praziquantel in the treatment of mixed S. haematobium and S. mansoni infections. Arzneimittel-Forschung, 31(3a), 605–608.

Rezende, G. L. D. (1985). Survey in the clinical trials achieved in Brazil comparing praziquantel and oxamniquine in the treatment of mansoni schistosomiasis. Revista do Instituto de Medicina Tropical de São Paulo, 27(6), 328–336.

Silva, L. C. D., Zeitune, J. M. R., Rosa-Eid, L. M. F., Lima, D. M. C., Antonelli, R. H., Christo, C. H., ... Carboni, A. D. C. (1986). Treatment of patients with schistosomiasis mansoni: A double blind clinical trial comparing praziquantel with oxamniquine. Revista do Instituto de Medicina Tropical de São Paulo, 28(3), 174–180.

Sukwa, T. Y. (1993). A community-based randomized trial of praziquantel to control schistosomiasis morbidity in schoolchildren in Zambia. Annals of Tropical Medicine and Parasitology, 87(2), 185–194.

References to excluded studies

Alderman, H., Konde-Lule, J., Sebuliba, I., Bundy, D., & Hall, A. (2006). Effect on weight gain of routinely giving albendazole to preschool children during child health days in Uganda: Cluster randomised controlled trial. BMJ, 333(7559), 122.

Awasthi, S., & Pande, V. K. (2001). Six-monthly de-worming in infants to study effects on growth. Indian Journal of Pediatrics, 68(9), 823–827.

Awasthi, S., Pande, V. K., & Fletcher, R. H. (2000). Effectiveness and cost-effectiveness of albendazole in improving nutritional status of pre-school children in urban slums. Indian Pediatrics, 37(1), 19–29.

Awasthi, S., Peto, R., Pande, V. K., Fletcher, R. H., Read, S., & Bundy, D. A. P. (2008). Effects of deworming on malnourished preschool children in India: An open-labelled, cluster-randomised trial. PLOS Neglected Tropical Diseases, 2(4), e223.

Awasthi, S., Peto, R., Read, S., Clark, S., Pande, V., & Bundy, D. (2013). Vitamin A supplementation every six months with retinol in 1 million pre-school children in north India: DEVTA, a cluster-randomised trial. Lancet, 381(9876), 1469–1477. https://doi.org/10.1016/s0140-6736(12)62125-4

Awasthi, S., Peto, R., Read, S., Richards, S. M., Pande, V., & Bundy, D. (2013). Population deworming every six months with albendazole in 1 million pre-school children in north India: DEVTA, a cluster-randomised trial. Lancet, 381(9876), 1478–1486. https://doi.org/10.1016/s0140-6736(12)62126-6

Bhoite, R. M., & Iyer, U. M. (2012a). Effect of deworming vs. iron-folic acid supplementation plus deworming on growth, hemoglobin level, and physical work capacity of schoolchildren. Indian Pediatrics, 49(8), 659–661.

Bhoite, R. M., & Iyer, U. M. (2012b). Sustainable effect of weekly iron folic acid supplementation on growth and haemoglobin status of school children. Current Pediatric Research, 16(1), 77–82.

Bobonis, G. J., Miguel, E., & Puri-Sharma, C. (2006). Anemia and school participation. Journal of Human Resources, XLI, 54(3), 692–721. https://doi.org/10.3368/jhr.XLI.4.692

Gateau, C., Leminier, G., & Labusquiere, R. (1972). Systematic anthelmintic treatment with thiabendazole in African schoolchildren. Annales de la Societe Belge de Medocite Tropicale, 52(2), 103–112.

Goto, R., Mascie-Taylor, C. G. N., & Lunn, P. G. (2009). Impact of anti-Giardia and anthelmintic treatment on infant growth and intestinal permeability in rural Bangladesh: A randomised double-blind controlled study. Transactions of the Royal Society of Tropical Medicine and Hygiene, 103(5), 520–529.

Gupta, M., Arora, K. L., Mithal, S., & Tandon, B. N. (1977). Effect of periodic deworming on nutritional status of ascaris-infested preschool children receiving supplementary food. Lancet, 2(8029), 108–110.

Gupta, M. C., & Urrutia, J. J. (1982). Effect of periodic antiscaric and antiagiarda treatment on nutritional status of preschool children. American Journal of Clinical Nutrition, 36(1), 79–86.

Joseph, S. A., Casapia, M., Montresor, A., Rahme, E., Ward, B. J., & Marquis, G. S., et al. (2015). The effect of deworming on growth in one-year-old children living in a soil-transmitted helminth-endemic area of Peru: A randomised controlled trial. PLOS Neglected Tropical Diseases, 9(10), e0004020.

Serene, A. J., Casapia, M., Lazarte, F., Rahme, E., Pezo, L., Blouin, B., & Gyorkos, T. W. (2015). The effect of deworming on early childhood development in Peru: A randomised controlled trial. SSM-Population Health, 1, 32–39.

Kaba, A. S., Luvwezo, M., Nzuzi, K., & Thienpont, D. (1978). Periodic anthelmintic treatment of schoolchildren in Zaire. (French) Le Traitement Anthelminthique Periodique D’enfants D’age Scolaire Au Zaïre. Annales de la Societe Belge de Medecine Tropicale, 58(3), 241–249.

Kruger, M., Badenhorst, C. J., Mansvelt, E. P. G., Laubscher, J. A., & Benadé, A. J. S. (1996). Effects of iron fortification in a school feeding scheme and anthelmintic therapy on the iron status and growth of sixty-eight-year-old schoolchildren. Food and Nutrition Bulletin, 17(1), 11–21.

Linnemayr, S., & Alderman, H. (2008). Almost random: Evaluating a large-scale randomised nutrition program in the presence of crossover. Journal of Development Economics, 96, 106–114.

Moser, W., Ali, S. M., Ame, S. M., Speich, B., Puchkov, M., Huwyler, J., ... Keiser, J. (2016). Efficacy and safety of oxantel pamoate in school-aged children infected with Trichuris trichiura on Pemba Island, Tanzania: A parallel, randomised, controlled, dose-ranging study. The Lancet Infectious Diseases, 16(1), 53–60.

Nokes, C., & Bundy, D. A. P. (1992). Trichuris trichiura infection and mental development in children. Lancet, 339(8791), 500.

Nokes, C., Grantham-McGregor, S. M., Sawyer, A. W., Cooper, E. S., & Bundy, D. A. (1992). Parasitic helminth infection and cognitive function in school children. Proceedings Biological Sciences/The Royal Society, 247(1319), 77–81.

Nokes, C., Grantham-McGregor, S. M., Sawyer, A. W., Cooper, E. S., Robinson, B. A., & Bundy, D. A. (1992). Moderate to heavy infections of Trichuris trichiura affect cognitive function in Jamaican school children. Parasitology, 104(3), 539–547.

Palupi, L., Schultink, W., Achadi, E., & Gross, R. (1997). Effective community intervention to improve hemoglobin status in preschoolers receiving once-weekly iron supplementation. The American Journal of Clinical Nutrition, 65(4), 1057–1061.

Pust, R. E., Binns, C. W., Weinhold, D. W., & Martin, J. R. (1985). Palm oil and pyrantel as child nutrition mass interventions in Papua New Guinea. (Comparative Study Research Support, Non-U.S. Gov't). Tropical and Geographical Medicine, 37(1), 1–10.

Reddy, V., Vijayaraghavan, K., & Mathur, K. K. (1986). Effect of deworming and vitamin A administration on serum vitamin A levels in preschool children. (Clinical Trial Research Support, Non-U.S. Gov't). Journal of Tropical Pediatrics, 32(4), 196–199.
References to ongoing studies

Leung, J. M., Hong, C. T. T., Trung, N. H. D., Thi, H. N., Minh, C. N. N., Thi, T. V., ... Hoang, N. L. T. (2016). The impact of albendazole treatment on the incidence of viral and bacterial-induced diarrhoea in school children in southern Vietnam: Study protocol for a randomized controlled trial. Trials, 17(1), 279.

Additional references

Aiken, A. M., Davey, C., Hargreaves, J. R., & Hayes, R. J. (2015). Re-analysis of health and educational impacts of a school-based deworming programme in western Kenya: A pure replication. International Journal of Epidemiology, 44(5), 1572–1580.

Austin, P. C. (2009). Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Statistics in Medicine, 28(25), 3083–3107.

Azomahou, T., Diallo, F., Raymond, W., & Diagne, A. (2014). The harmony of programs package: quasi-experimental evidence on deworming and canteen interventions in rural Senegal (working paper). Retrieved from UNU-MERIT working paper series. Available at: https://www.econstor.eu/handle/10419/123057

Balschim, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., ... Norris, S. (2011). GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology, 64(4), 401–406.

Bell, M. L., Fiero, M., Horton, N. J., & Hsu, C.-H. (2014). Handling missing data in RCTs: A review of the top medical journals. BMC Medical Research Methodology, 14(1), 118.

Biovin, M., & Giordani, B. (1993). Improvements in cognitive performance for school children in Zaire, Africa, following an iron supplement and treatment for intestinal parasites. Journal of Pediatric Psychology, 18(2), 25.

Bundy, D. A., Kremer, M., BLEAKLEY, H., Jukes, M. C., & Miguel, E. (2009). Deworming and development: Asking the right questions, asking the questions right. PLOS Neglected Tropical Diseases, 3(1), e362.

Campbell, S. J., Nery, S. V., Doi, S. A., Gray, D. J., Soares Magalhaes, R. J., McCarthy, J. S., ... Clements, A. C. (2016). Complexities and perplexities: A critical appraisal of the evidence for soil-transmitted helminth infection-related morbidity. PLOS Neglected Tropical Diseases, 10(5), e0004566. https://doi.org/10.1371/journal.pntd.0004566

Colley, D. G., Bustinayd, A. L., Secor, W. E., & King, C. H. (2014). Human schistosomiasis. The Lancet, 383(9936), 2253–2264.

Crawley, J. (2004). Reducing the burden of anaemia in infants and young children in malaria-endemic countries of Africa: From evidence to action. The American Journal of Tropical Medicine and Hygiene, 71(Suppl 2), 25–34.

Croke, K., Hicks, J. H., Hsu, E., Kremer, M., & Miguel, E. (2016). Does mass deworming affect child nutrition? Meta-analysis, cost-effectiveness, and statistical power. Retrieved from https://www.ncbi.nlm.nih.gov/papers/w22382.pdf

Dagne, G. A., Brown, C. H., Howe, G., Kellam, S. G., & Liu, L. (2016). Testing moderation in network meta-analysis with individual participant data. Statistics in Medicine, 35(15), 2485–2502.

Danso-Apiah, A., Olliaro, P. L., Donegan, S., Sinclair, D., & Utzinger, J. (2013). Drugs for treating Schistosoma mansoni infection. Cochrane Database of Systematic Reviews (2).

De-Regil, L. M., Jefferds, M. E. D., Sylvestsky, A. C., & Dowswell, T. (2011). Intermittent iron supplementation for improving nutrition and development in children under 12 years of age. The Cochrane Library.

dier, B., Campos Ponce, M., van de Bor, M., Doak, C. M., & Polman, K. (2014). Helminth infections and micronutrients in school-age children: A systematic review and meta-analysis. The American Journal of Clinical Nutrition, 99(6), 1499–1509.

Debray, T. P., Schuit, E., Efthimiou, O., Reitsma, J. B., Ioannidis, J. P., Salanti, G., ... Workpackage, G. (2018). An overview of methods for network meta-analysis using individual participant data: When do benefits arise? Statistical Methods in Medical Research, 27(5), 1351–1364.

Dirren, H., Logman, M. H., Barclay, D. V., & Freire, W. B. (1994). Altitude correction for hemoglobin. European Journal of Clinical Nutrition, 48(9), 625–632.

Donegan, S., Williamson, P., D’Alessandro, U., & Smith, C. T. (2012). Assessing the consistency assumption by exploring treatment by covariate interactions in mixed treatment comparison meta-analysis: Individual patient-level covariates versus aggregate trial-level covariates. Statistics in Medicine, 31(29), 3840–3857.

Early Breast Cancer Trialists’ Collaborative Group. (1990). Treatment of early breast cancer. 1. Worldwide evidence 1985–1990 (Vol. 1). USA: Oxford University Press.

Frisi, H., Mwaniki, D., Omondi, B., Muniu, E., Thioug’t, F. W., Ouma, J. H., ... Michaelsen, K. F. (2003). Effects on haemoglobin of multi-micronutrient supplementation and multi-helminth chemotherapy: A randomized, controlled trial in Kenyan school children. European Journal of Clinical Nutrition, 57(4), 573–579.

Grimes, J. E., Croll, D., Harrison, W. E., Utzinger, J., Freeman, M. C., & Templeton, M. R. (2014). The relationship between water, sanitation and schistosomiasis: A systematic review and meta-analysis. PLOS Neglected Tropical Diseases, 8(12), e3296.

Groenwold, R. H., Moons, K. G., & Vandenbroucke, J. P. C. (2014). Randomized trials with missing outcome data: How to analyze and what to report. Canadian Medical Association Journal, 186(15), 1153–1157.
low-income and middle-income countries: A systematic review and network meta-analysis. The Lancet Global Health, 5(1), e40–e50.

WHO (2017). Guideline: Preventive chemotherapy to control soil-transmitted helminth infections in at-risk population groups, Geneva: WHO. Licence: CC BY-NC-SA 3.0 IGO.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Welch V, Ghogomu E, Hossain A, et al. Mass deworming for improving health and cognition of children in endemic helminth areas: A systematic review and individual participant data network meta-analysis. Campbell Systematic Reviews. 2019;15:e1058.

https://doi.org/10.1002/cl2.1058